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Although life expectancy has steadily increased in the United States (U.S.), 
socioeconomic disparities in risk for mortality persist, indicating the need to identify novel risk 
factors linking socioeconomic position (SEP) and mortality in the U.S. Several persistent 
pathogens pattern by SEP in early life and have been implicated in cardiovascular disease (CVD) 
and other chronic diseases later in life via pathogen-specific effects and non-specific 
inflammatory pathways. Therefore, individual persistent pathogens and increased total pathogen 
burden may serve as novel risk factors for mortality. 
Using data from a U.S. representative sample of persons 25 years of age and older from 
the National Health and Nutrition Examination Survey III (1988-1994), we examined the 
association between cytomegalovirus (CMV) seropositivity, levels of C-reactive protein (CRP), a 
marker of systemic inflammation, and risk for all-cause/CVD-related mortality. In addition, we 
examined the association between summed total pathogen burden with CMV, herpes simplex 
virus type 1 (HSV-1) and -2 (HSV-2) and/or Helicobacter pylori (H. pylori) and all-cause/CVD-
related mortality. Last, we assessed the extent to which there is variability in risk for all-
cause/CVD-related mortality, within and across pathogen burden levels, according to the specific 
combination of pathogens for which individuals are seropositive. 
The main findings from this work indicate that (1) CMV seropositivity is associated with 
increased risk for all-cause mortality, but not CVD-related mortality. However, the greatest risk for 
all-cause/CVD-related mortality is for the combined effect of CMV seropositivity and high CRP 
level, (2) there is an absence of a graded relationship between increased summed pathogen 
burden with CMV, HSV-1, HSV-2 and/or H. pylori and all-cause/CVD-related mortality and (3) 
there is variability in risk for all-cause/CVD-related mortality both within and across pathogen 
burden levels, according to pathogen combination, not accounted for by summed pathogen 
burden variables and the combined effect of seropositivity for specific combinations of pathogens 
are statistically significantly associated with all-cause (CMV and HSV-2 as well as CMV, HSV-1 
and HSV-2) and CVD-related (CMV and HSV-2 as well as HSV-2 and H. pylori) mortality. 
Implications of these findings for future interventions targeting the prevention or immune control 







Chapter 1  
Introduction 
1.1 Introduction 
 There are vast disparities in mortality according to socioeconomic position (SEP).
1-11
 
Furthermore, although life expectancy has increased steadily over the past 50 years, it is 
increasing at a greater rate among those of high SEP and the gap in life expectancy between 
those of low and high SEP is ever widening.
12-15
 Adler et al., describe a pathway in which SEP 
(education, occupation and/or income level) influences health via a combination of exposure to 
environments that impact health and one‟s ability to adapt to these environments.
16
 (see Figure 
1.1 on page 4) Persons living in poverty are disproportionately exposed to physical environments 
such as overcrowding, inadequate housing, exposure to toxins, pollution, carcinogens and 
pathogens as well as social environments such as unemployment, crime, discrimination and lack 
of job control.
16-22
 In addition, persons of low SEP have access to fewer resources to cope with 
these environmental stressors such as lack of access to health care and healthy food choices, 
safe exercise environments and social support networks.
16-22
 Adler et al. propose that increased 
levels of environmental stressors combined with fewer resources impacts health in three ways: 1) 
exposures (toxins, carcinogens and pathogens), 2) adoption of detrimental health behaviors, and 
3) the physiological response to stress.
17
 
 The majority of research attempting to explain SEP disparities in health has focused on 
SEP patterning of health behavior and physiologic response to stress.
23-25
 Persons living in 
poverty often adopt detrimental health behaviors including smoking, alcohol and drug use, 
decreased physical activity and poor diet as coping mechanisms in response to stress and few 
social resources.
18,21,26-28
 These behaviors in turn have been shown to increase one‟s risk for 
chronic diseases such as cardiovascular disease (CVD), diabetes and physical and cognitive 
impairment and consequently mortality.
29-33
 In addition to behavioral changes, persons of low 
SEP undergo physiologic changes when exposed to stressful physical and social environments. 
The stress response can become dysfunctional during exposure to chronic stressors in which the 
adaptation response is frequently initiated and may be ineffectively terminated, causing wear and 
tear on the body due to failure of the body‟s physiologic systems to properly adapt to 
stress.
21,25,27,34-36
 As a result, levels of blood pressure, stress hormones and inflammatory 
markers are elevated over time, leading to organ damage and immune dysfunction.
35,36
 Although, 





risk for mortality, these factors do not fully explain SEP disparities in mortality
23-25,37
, thus it 
remains essential to investigate novel pathways linking SEP and mortality.  
 Over the past forty years, numerous persistent pathogens which pattern by SEP early in 
life, have been implicated in later-life CVD and more recently, other chronic diseases of aging 
with inflammation-related etiology.
38-44
 Persistent pathogens are linked to chronic disease via 
direct, pathogen-specific effects such as in the case of CVD, in which certain pathogens invade 
vascular tissues and trigger atherogenesis.
45-49
 In addition, initial infection as well as reactivation 
with persistent pathogens triggers the release of acute phase proteins and increases levels of 
inflammatory markers such as C-reactive protein (CRP), which have been linked to CVD and 
other chronic diseases.
50-56
 Thus, persistent pathogens have been hypothesized as a novel 
mediator in the pathway between SEP and chronic disease as well as mortality, especially in 
conjunction with increased levels of inflammatory markers.
57-62
 Furthermore, increased total 
pathogen burden is thought to increase risk for chronic disease and mortality due to an 
accumulation of pathogen-specific effects and increased levels of systemic inflammation.  
A measure of total pathogen burden often utilized by researchers interested in examining 
the association between total pathogen burden and mortality is „summed pathogen burden‟. 
Summed pathogen burden is defined as the total number of pathogens an individual tests 
seropositive for, based on antibody response, and allows researchers to examine whether there 
is a graded relationship between the total number of pathogens an individual is seropositive for 
(i.e., summed pathogen burden level) and mortality, regardless of pathogen type. Unfortunately, 
there are some shortcomings related to the use of summed pathogen burden variables for 
examining the relationship between total pathogen burden and risk for mortality because 
variables representing summed pathogen burden have not permitted an assessment of the 
impact of specific types or combinations of pathogens on health/mortality outcomes. 
The objectives of this dissertation are: 1) to examine the relationship between 
seropositivity for cytomegalovirus (CMV), a persistent pathogen linked to several chronic disease 
outcomes, elevated CRP and all-cause/CVD-related mortality, 2) to examine the relationship 
between summed pathogen burden with four pathogens previously implicated in the etiology of 
several chronic diseases (CMV, herpes simplex virus -1(HSV-1) and 2 (HSV-2), and Helicobacter 
pylori (H. pylori) in all-cause/CVD-related mortality, and 3) to examine the association between 
the specific combinations of these four pathogens and risk for all-cause/CVD-related mortality 
and assess the extent to which use of summed pathogen burden variables in models examining 
the association between total pathogen burden and mortality limit the identification of the specific 
combinations of pathogens that most increase risk for mortality, using data from a U.S. 





1.2 Specific Aims and Hypotheses 
Aim 1: Examine the association between seropositivity for CMV, CRP level and risk for CVD-
related/all-cause mortality.  
Hypothesis 1a: Seropositivity for CMV at baseline will predict an increased risk for all-
cause and CVD-related mortality. 
Hypothesis 1b: The observed association between CMV and risk for all-cause and CVD-
related mortality will be augmented among participants with high CRP level. 
Aim 2: Examine the association between summed total pathogen burden with CMV, HSV-1, HSV-
2 and/or H. pylori and risk for all-cause and CVD-related mortality. 
Hypothesis 2a: Summed total pathogen burden will have a graded relationship with risk 
for all-cause mortality. 
 Hypothesis 2b: Summed total pathogen burden will have a graded relationship with risk 
for CVD-related mortality. 
Aim 3: To estimate the combined effect of seropositivity to each possible combination of four 
pathogens (CMV, HSV-1, HSV-2 and H. pylori) on risk for all-cause/CVD-related mortality and to  
assess the extent to which, use of summed pathogen burden variables in models examining the 
association between total pathogen burden and mortality, limit our ability to make inferences 
about the specific pathogens which alone, or in combination most increase risk for death.  
Hypothesis 3a: The combined effect of each combination of pathogens on risk for all-
cause/CVD-related mortality will not be uniform within each pathogen burden level. 
Hypothesis 3b: The combined effect of different combinations of pathogens on risk for all-
cause/CVD-related mortality will vary across pathogen burden levels such that the risk for 
mortality associated with each specific combination of pathogens will not necessarily be higher 
than the risk for mortality for all combinations of fewer pathogens.  
1.3 Background  
Socioeconomic Position, Chronic Disease and Mortality in the United States 
The relationship between chronic disease and mortality is well-established.
63
 Although 
death rates (per 100,000 per year) have decreased overall in the past 30 years from 1242 in 1970 
to 845 in 2002, the absolute number of deaths from the six leading causes of death; heart 
disease, cancer, stroke, chronic obstructive pulmonary disease, accidents and diabetes, the 
majority of which are chronic diseases, continues to increase.
64
 Furthermore, gains in life 
expectancy have been primarily among those of higher socioeconomic position.
12-15
 For example, 
Meara et al., examined changes in mortality according to education level in non-Hispanic blacks 
and whites from 1981-2000, finding that the educational gaps in life expectancy increased by 
about 30% during this time period and that the widening gap cannot be attributed to increased 
racial or gender differences in mortality.
14
 Similar results were found recently by Cristia, who 







difference in life expectancy for those in the top lifetime earning quintile versus the bottom quintile 
increased by 30 percent for men and almost doubled for women over this time period.
15
 
Psychosocial Model Linking Socioeconomic Position and Health 
Research over the past 30 years has pointed to both structural and physiologic 
mechanisms by which living in poverty may impact health.
16-19,21,22,65
 Adler et al., describe a 
pathway in which SEP (education, occupation and/or income level) influences health via a 
combination of exposure to environments that impact health and one‟s ability to adapt to these 
environments (see Figure 1.1 below).
17
 Persons living in poverty are disproportionately exposed 
to physical environments such as overcrowding, inadequate housing, exposure to toxins, 
pollution, carcinogens and pathogens as well as social environments such as unemployment, 
crime, discrimination and lack of job control.
16-19,21,22,65
  In addition, persons of low SEP have 
access to fewer resources to cope with these environmental stressors such as lack of access to 
health care and healthy food choices, safe exercise environments and social support networks.
16-
19,21,22,65
 Adler et al. propose that increased levels of environmental stressors combined with fewer 
resources impacts health in three ways; 1) exposures (toxins, carcinogens and pathogens), 2) 





Figure 1.1 Model of the Pathways by which Socioeconomic Status Influences Health
17
 
The majority of research attempting to explain SEP disparities in health has focused on 
SEP patterning of health behavior and physiologic response to stress.
23,25,66





poverty often adopt detrimental health behaviors including smoking, alcohol and drug use, 
decreased physical activity and poor diet as coping mechanisms in response to stress and have 
few social resources.
18,21,26-28
 These behaviors in turn have been shown to increase one‟s risk for 
chronic diseases such as cardiovascular disease (CVD), diabetes and physical and cognitive 
impairment and consequently mortality.
29-33
 In addition to behavioral changes, persons of low 
SEP undergo physiologic changes when exposed to stressful physical and social environments. 
The stress response can become dysfunctional during exposure to chronic stressors in which the 
adaptation response is frequently initiated and may be ineffectively terminated, causing wear and 
tear on the body due to failure of the body‟s physiologic systems to properly adapt to stress.
21, 25, 
27, 34-36
 As a result, levels of blood pressure, stress hormones and inflammatory markers are 
increased over time, leading to organ damage and immune dysfunction.
35, 36
 
However, neither traditional health behaviors nor the physiologic response to stress have 
been found to fully explain SEP disparities in mortality.
23,25,37,66
 A recent study by Rask et al., 
examined the relationship between SEP, health behavior and mortality in subjects 18 years and 
older in NHANES III.
23
 The authors found that the relationship between income (relative to the 
poverty level) and mortality was not significantly attenuated after controlling for age, gender, self-
reported health status, behavioral risk factors such as smoking status, waist circumference and 
physical activity as well as clinical risk factors.
23
 Likewise, Seeman et al., examined whether a 
cumulative index of biologic risk (i.e., allostatic load) mediated the relationship between education 
level and mortality among subjects aged 70-79 from a 7-year follow-up study from the MacArthur 
Study of Successful Aging (1988-1995), finding that it explained only 35.4% of the difference in 
mortality risk between those with less than high school education versus high school or greater.
25
 
Although life expectancy is increasing overall in the United States the absolute number of 
deaths from chronic diseases continues to increase, the gap in life expectancy between those of 
low and high SEP is ever widening and traditional risk factors hypothesized to lie in the pathway 
between SEP and disease don‟t completely explain the SEP patterning of disease observed in 
the United States. Thus, it remains important to explore novel risk factors for chronic disease and 
mortality. Over the past several decades, a growing body of evidence has implicated persistent 
pathogens which pattern according to SEP in early life in the etiology of cardiovascular disease 




Persistent pathogens are linked to chronic disease via direct, pathogen-specific effects 
such as in the case of CVD, in which certain pathogens invade vascular tissues and trigger 
atherogenesis.
45-49
 In addition, initial infection as well as reactivation with persistent pathogens 
triggers the release of acute phase proteins and increases levels of inflammatory markers such 
as CRP, which have been linked to CVD and other chronic diseases.
50-56
 Therefore, persistent 





chronic disease as well as mortality, especially in conjunction with increased levels of 
inflammatory markers.
57-62
 Research examining the relationship between persistent pathogens, 
inflammation and mortality is needed to better understand the role of these factors in determining 
risk for death in the general U.S. population. 
1.4 Cytomegalovirus, Inflammation, Chronic Disease and Mortality 
CMV is a highly transmissible and prevalent beta herpesvirus.
67,68
 This pathogen is never 
cleared from the body, persisting in a number of tissues via hypothesized mechanisms including 
chronic productive infection and/or latent infection with periodic subclinical reactivation.
68,69
 
Recently, CMV has been linked to a variety of chronic diseases with an inflammatory component 




, cognitive decline including vascular 
dementia
38,74
 and functional impairment.
39,57,75
 
Cytomegalovirus, Inflammation and Chronic Disease 
 The specific mechanisms responsible for the association between CMV and various 
chronic diseases are related to pathogen-specific effects and to have an inflammatory 
component. For example, in terms of increasing risk for CVD, CMV exerts several pathogen-
specific effects that increase risk for CVD. CMV is also capable of invading vascular tissues by 
either directly infecting the vessels of the heart where it replicates at low levels, or when it is 
delivered to the vessel wall by infected circulating monocytes arriving at sites of existing 
cardiovascular injury or inflammation.
76
 Both CMV antigen and DNA previously identified in 
atherosclerotic vessels of the human cardiovascular system 
45,77,78
 The presence of CMV in the 
vessel walls may induce smooth muscle cell proliferation and migration, increased uptake of 
oxidized low-density lipoprotein and expression of cytokines and chemokines as well as 
increased procoagulant activity by endothelial cells.
79-82
 CMV may also cause vascular damage 
without direct invasion as a result of molecular mimicry, whereby viral antigens trigger an immune 
response cross-reacting on self-peptides expressed on uninfected host tissues.
79,83,84
  For 
example, two CMV-derived proteins, UL122 and US28, are homologous to an amino acid 
sequence at position 153-160 of heat shock protein (HSP) 60.
85,86
 Thus, there are several 
pathogen-specific effects by which CMV directly influences the development of atherosclerosis 
and subsequent CVD outcomes.  
 In addition, to exerting specific effects, CMV has been linked to several other chronic 
diseases with inflammation-related etiology such as physical impairment, cognitive decline and 
cancer.
38,39,57,72-75
 Reactivations or superinfections may result in higher titers of CMV 
immunoglobulin G (IgG) antibodies and increased levels of pro-inflammatory cytokines such as 
interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α).
50,87,88
 CRP levels also increase as a 
consequence of reactivation or leakage of the virus from host cells, via the action of IL-6 
produced in the liver.
80,89,90
 Elevated levels of these inflammatory markers have been linked to 
CVD as well as a myriad of other chronic disease conditions.
50-56





CVD-related and all-cause mortality through pathogen-specific effects for CVD and via 
inflammation-related pathways. 
Epidemiologic Studies Examining the Association between Cytomegalovirus and Mortality 
Few studies have examined the association between CMV, inflammation and all-
cause/CVD-related mortality. A recent study by Roberts et al., examined the relationship between 
CMV antibody titer and all-cause/CVD mortality among elderly Latinos finding that subjects with 
CMV IgG antibody titers in the highest quartile had 1.43 (95% CI: 1.14, 1.79) times higher risk for 
all-cause mortality and 1.35 (95% CI: 1.01, 1.80) times higher risk for CVD mortality in models 
adjusted for age, gender, education and comorbidity index.
58
 The authors found the effect of CMV 
on mortality was partially mediated by a composite measure of two inflammatory markers, TNF-α 
and IL-6, but not CRP since it was unrelated to mortality in their study population.
58
 In contrast, 
Blankenberg et al. found CMV to be associated with cardiac mortality among persons with 
existing coronary artery disease (CAD) only in subjects with elevated IL-6 levels (hazard ratio 
(HR) 3.2, 95% confidence interval (CI): 1.4, 7.3) and not in those without IL-6 elevation, 




Also examining the effect of CMV antibody titers on mortality, Strandberg et al. assessed 
7-year risk for mortality in a small cohort of community-dwelling 75-90 year-olds with underlying 
CVD in Finland.
59
 The authors found that mortality was significantly greater among subjects in the 
highest CMV IgG quartile, compared with the lowest quartile and that this association remained 
significant after controlling for several covariates including CRP, suggesting that CRP did not 
mediate this pathway.
59
 Furthermore, Muhlestein et al. examined the association between 
seropositivity to CMV, H. pylori and Chlamydia pneumoniae (C. pneumoniae) infections, as well 
as high CRP level and mortality among patients with a mean age of 65 years that were 
predominantly male and had angiographically demonstrated CAD.
92
  Of the three pathogens 
assessed, only seropositivity to CMV was significantly predictive of mortality. The authors also 
found that risk for mortality was greatest among CMV seropositive subjects with CRP levels in the 
highest tertile, suggesting a joint effect of CMV seropositivity and high CRP level on mortality 
among their sample of individuals with underlying CAD.
92
 
Although these studies suggest an association between CMV and mortality, they were 
conducted in predominantly older age populations, of specific gender or race/ethnic groups 
and/or among participants who have underlying CAD or CVD health conditions.
57-59,91,92
  
Moreover, the role of inflammatory markers such as IL-6, TNF-α and CRP as mediators or effect 
modifiers of the relationship between CMV and mortality is unclear.
57-59,91,92
  Therefore, the first 
aim of this dissertation examines whether seropositivity for CMV predicts all-cause as well as 
CVD-related mortality and whether CRP mediated or modified these relationships in a nationally 







1.5 Pathogen Burden, Chronic Disease and Mortality 
In addition to CMV, over the past forty years, numerous other persistent pathogens which 
pattern by SEP early in life, have been implicated in later-life CVD and more recently, other 
chronic diseases of aging with inflammation-related etiology.
41,44,72,73,93
 Other persistent 
pathogens, such as herpes simplex -1 (HSV-1) and 2 (HSV-2), Epstein Barr Virus (EBV), and 
various bacterial pathogens such as C. pneumoniae, H. pylori, Porphyromonas gingivalis, 
Actinobacillus actinomycetemcomitans have also been linked to chronic disease through direct 
pathological effects on organs and tissue as well as through more non-specific inflammatory 
pathways. For example, regarding CVD, some of these pathogens are capable of invading 
vascular tissues, causing vascular damage and triggering atherosclerotic processes such as 
smooth muscle cell proliferation.
45-49,94-106
 Pathogens such as CMV and H. pylori, can also induce 
vascular damage without infecting the vasculature by triggering an immune response via cross-
reacting on self-peptides expressed on uninfected host tissues, known as molecular 
mimicry.
83,84,107,108
  In addition to these pathogen-specific effects on CVD, pathogens such as H. 
pylori, Epstein Barr virus and recently, CMV, have been linked directly to various cancers through 
cellular processes such as cell migration, apoptosis and cell proliferation.
72,73,109-111
 Thus, 
increased pathogen burden is thought to increase risk for chronic disease, in part, via the 
accumulation of pathogen-specific effects on chronic diseases. 
Increased pathogen burden is also thought to impact the development of chronic 
diseases via increasing systemic inflammation.
50-56
 Once acquired, persistent viral pathogens 
such as herpesviruses undergo periodic reactivation during times of physical or psychosocial 
stress, immunosupression, and during the aging process and chronic bacterial infections such as 
H. pylori and C. pneumoniae develop persistent antibodies, which in turn, stimulate an immune 
response and increased levels of inflammatory markers.
112-117
 Increased levels of inflammatory 
markers, such as CRP have in turn, been associated with increased risk for CVD as well as other 
chronic disease outcomes including physical and cognitive impairment, metabolic disorders and 
cancers 
38,39,41,44,52,53,55,72,73,75,93,118
 For example, Figure 1.2 on the next page, illustrates the 
contribution of pathogen-specific effects as well as non-specific inflammatory effects of selected 
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Figure 1.2 Illustration of the Accumulation of Both Pathogen-Specific Effects and Non-
Specific Inflammatory Effects of Various Pathogens For Increasing Risk for 
Cardiovascular Disease. 
Thus, persistent pathogens have been linked to both CVD and other chronic diseases 
through a combination of pathogen-specific effects as well as through non-specific effects of 
increased inflammation. For these reasons, increased pathogen burden may also be associated 
with increased risk for mortality as well.  
Summed Pathogen Burden 
Due to an accumulation of both pathogen-specific effects as well as overall increased 
levels of inflammation, it has been hypothesized that the more pathogens an individual is 
seropositive for, the greater their risk for chronic disease and mortality (see Figure 1.3 on next 
page).
94
 In other words, it is thought that seropositivity for any two pathogens increases risk 
beyond that of seropositivity to a single pathogen, seropositivity for any three pathogens 
increases risk for disease beyond seropositivity for one or two pathogens, and so forth, 





















































Number of Pathogens Individuals Are Seropositive For-Summed Pathogen Burden  
Figure 1.4 Illustration of Hypothesized Monotonic Relationship between Increasing 






As a result, studies typically construct summed pathogen burden variables when 
modeling the relationship between total pathogen burden and mortality. Summed pathogen 
burden is defined as the total number of pathogens an individual tests seropositive for, based on 
antibody response, and allows researchers to examine whether there is a graded relationship 
between the total number of pathogens an individual is seropositive for (i.e., summed pathogen 
burden level) and mortality, regardless of pathogen type. Despite the hypothesized relationship 
between increased summed pathogen burden and numerous chronic diseases, very few studies 
have examined the association between summed pathogen burden and mortality. The few 
studies that exist were primarily conducted among persons with existing CVD, of older age and 
from specific race/ethnic groups limiting their generalizability to the general population.
60-62,119
 
Thus, there is a need to examine whether there is a graded relationship between summed 
pathogen burden and mortality in the U.S. general population. 
Epidemiologic Studies Examining the Association between Summed Pathogen Burden and 
Mortality 
Although several studies have examined the association between summed pathogen 
burden, inflammation and various chronic disease few studies have examined the relationship 
between summed pathogen burden and all-cause/CVD-related mortality and results across 
studies are conflicting.
60-62,119
 Most recently, a study by Elkind et al., measured the association 
between a constructed infectious burden index (sum of the beta coefficients for the effect of each 
pathogen for which individuals were seropositive on risk for stroke) and vascular, non-vascular 
and all-cause deaths among subjects 40 years of age and older (mean age 68.4) from 
Manhattan, New York, without history of stroke.
119
  The authors found that infectious burden 
index (including C. pneumoniae, CMV, HSV-1, HSV-2 and H. pylori), was associated with an 
increased risk for nonvascular deaths (HR per standard deviation change in IB 1.23, 95% CI 1.04, 
1.45) in the fully adjusted model.
119
 However, after confounder adjustment, the index was no 
longer statistically significantly associated with risk for vascular deaths or deaths from all 
causes.
119
 In contrast, Zhu et al., examined the relationship between summed pathogen burden 
with CMV, Hepatitis A, HSV-1 and 2 and all-cause death among a mostly male cohort of Utah 
residents, with a mean age of 65.3 years and existing CAD.
60
 The authors found a significant 
trend (p-value = 0.020) in risk for death from all-causes with increasing pathogen burden 
(although individual effects were not statistically significant).
60
 
Two other studies by Rupprecht et al. and Espinola-Klein et al., examined the association 
between summed pathogen burden with eight pathogens (HSV-1, HSV-2, CMV, Epstein-Barr 
virus, Haemophilus influenzae, C. pneumoniae  Mycoplasma pneumoniae and H. pylori) and 
CVD-related mortality among German subjects with existing coronary artery disease (CAD).
61,62
 





pathogen burden of 4-5 and 6-8 pathogens compared to seropositivity for 0-3 pathogens.
61,62
 
Rupprecht et al. further examined the association between increased pathogen burden with 
bacterial and viral pathogens and CVD-related mortality, separately (comparing seropositivity for 
2 vs. 0-1 pathogens and for 3-4 vs. 0-1 pathogens) finding that the association between 
increased pathogen burden with herpesviridae and CVD-related mortality was stronger than that 
with bacterial burden.
61
 However, the groupings were not mutually exclusive, thus it is not 
possible to completely discern the effects of viral pathogen burden alone from co-infection with 
viral and bacterial pathogens in terms of risk for CVD-related mortality from the analysis.
61
  
These studies suggest a graded association between summed pathogen burden and all-
cause/CVD-related mortality among persons with existing CVD but not among those without 
existing CVD. However, these previous studies were conducted among older populations, mostly 
consisted of persons with existing CVD and from specific geographic regions (i.e. Utah, New York 
and Germany).
60-62,119
 Therefore, further research is needed to determine the association 
between summed pathogen burden, inflammation and all-cause/CVD-related mortality among the 
U.S. general population. The second aim of this dissertation will examine whether there is a 
graded relationship between increasing pathogen burden with four persistent pathogens (CMV, 
HSV-1, HSV-2 and/or H. pylori, previously implicated in CVD and other chronic diseases, and 
CVD-related/all-cause mortality in a U.S. representative population of persons ≥ 25 years of age 
from NHANES III.  
1.6 Summed Pathogen Burden- Issues in Measurement 
Summed pathogen burden variables may be useful for examining whether there is a 
graded relationship between the total number of pathogens an individual is seropositive for (i.e., 
summed pathogen burden level) and mortality, regardless of pathogen type. However, there are 
several measurement issues that limit the use of this variable for assessing other factors that my 
play an important role in determining risk for mortality such as seropositivity for specific 
combinations of pathogens. 
There are two main reasons why use of the summed pathogen burden variable may not 
provide a complete assessment of risk for mortality related to persistent pathogens. First, in 
models examining the association between summed pathogen burden and mortality, all persons 
seropositive to a given number of pathogens (i.e., classified as having the same summed 
pathogen burden level) are estimated as having the same risk for disease/mortality by the model, 
regardless of the specific combination of pathogens for which an individual is seropositive (see 
Table 1.1 on next page). For example, when two individuals are categorized as having a summed 
pathogen burden level of two, one of these individuals may be seropositive for pathogens A and 
C and the other may be seropositive for pathogens B and D. Thus, these two individuals would be 
categorized as having a summed pathogen burden level of two and therefore be estimated as 





pathogens. Second, assuming a monotonic relationship between summed pathogen burden level 
and risk for mortality whereby an increase in summed pathogen burden level leads to an 
increased risk for mortality (see Figure 1.2, page 9) implies that the risk for mortality associated 
with any specific combination of pathogens is greater than risk for mortality associated with all 
combinations of fewer pathogens, regardless of pathogen type.   
 
Table 1.1 An Illustration of the Potential Heterogeneity of Pathogen 
Combinations Within Pathogen Burden Level 
 Pathogen Types  
 A B C D  
Pathogen Combinations Serostatus Pathogen Burden Level 
1 + - - - 
1 
2 - + - - 
3 - - + - 
4 - - - + 
5 + + - - 
2 
6 + - + - 
7 + - - + 
8 - + + - 
9 - + - + 
10 - - + + 
11 + + + - 
3 
12 + - + + 
13 + + - + 
14 - + + + 
15 + + + + 4 
 
Although a graded relationship between total pathogen burden and mortality may exist in 
certain populations, there is also evidence that pathogens may biologically interact such that 
combined seropositivity could increase or decrease risk for mortality.
120,121,122
 While summed 
pathogen burden variables may be useful for examining the hypothesis that “more is worse” when 
it comes to total pathogen burden and risk for mortality, limiting the examination of the 
relationship between total pathogen burden and mortality to this variable, hinders an assessment 
of other factors that might play an important role in the association between total pathogen 
burden and mortality such as the specific  combinations  of pathogens, for which individuals are 
seropositive. Thus, the use of summed pathogen burden variables for examining the association 





associated with different combinations of pathogens both within pathogen burden levels and 
across pathogen burden levels.  
While measures of summed pathogen burden may be useful for examining the 
hypothesis that “more is worse”, further research that also incorporates an assessment of the 
relationship between specific  types of persistent pathogens alone or in combination and risk for 
mortality is needed. To our knowledge, no study has explicitly examined the extent to which the 
use of summed pathogen burden variables, limits the ability of researchers to make inferences 
regarding the contribution of specific types of pathogens and interactions among pathogens to 
mortality outcomes. The third aim of this dissertation addresses these issues by 1) estimating the 
combined effects of seropositivity to four persistent pathogens (CMV, HSV-1, HSV-2 and H. 
pylori) on all-cause/CVD-related mortality in a U.S. representative population of individuals ≥ 25 
years of age and older, and 2) examining the variability in risk for mortality associated with 
specific combinations of pathogens within and across pathogen burden levels.  
1.7 Public health significance 
Although life expectancy is increasing overall in the United States the absolute number of 
deaths from chronic diseases continues to increase, the gap in life expectancy between those of 
low and high SEP is ever widening and traditional risk factors hypothesized to lie in the pathway 
between SEP and disease don‟t completely explain the SEP patterning of disease observed in 
the United States. It remains important to explore novel risk factors for chronic disease and 
mortality. Over the past several decades, a growing body of evidence has implicated persistent 
pathogens, many of which pattern according to SEP in early life, in the etiology of cardiovascular 
disease (CVD) and other chronic diseases.
50-56
 Persistent pathogens are thought to impact risk 
for chronic disease and mortality in part via pathogen-specific effects and in part, because 
infection increases inflammatory levels. In addition, elevated inflammation is potentially a marker 
of “reactive” infection which may lead to exacerbated damage by persistent pathogens. Elevated 
inflammatory markers are in turn, associated with risk for chronic diseases such as CVD, physical 
impairment and metabolic disorders.
50-56
  
Thus, it has been hypothesized that individual pathogens impact risk for chronic disease 
and consequently mortality via both pathogen-specific effects and by contributing to elevated 
inflammation. However, the role of particular pathogens, in conjunction with elevated 
inflammation in determining risk for mortality has primarily been examined in older populations of 
specific race/ethnicity and gender, thus the association between these factors in the general U.S. 
adult population is not clear. Furthermore, increased total pathogen burden is thought to also play 
an important role in determining risk for mortality than seropositivity due to the accumulation of 
pathogen-specific effects and increased inflammation. However, it is also not clear whether there 
is a graded relationship between summed pathogen burden and all-cause/CVD-related mortality 





useful for examining whether there is a monotonic relationship between summed pathogen 
burden and mortality, may limit the ability of researchers to make inferences regarding the 
contribution of specific types of pathogens and interactions among pathogens for risk for 
mortality. Research is needed to determine whether seropositivity for specific combinations of 
pathogens plays an important role in determining risk in addition to the role of increased numbers 
of pathogens and to assess the extent to which the use of summed pathogen burden variables in 
models assessing the relationship between total pathogen burden and mortality limit the ability for 
researchers to make inferences about the pathogens that are most detrimental to health in the 
general population.   
The first aim of this dissertation examines whether seropositivity for CMV, a persistent 
pathogen implicated in several chronic disease outcomes, in conjunction with elevated CRP level 
increases risk for all-cause/CVD-related mortality. The second aim examines whether there is a 
graded relationship between summed pathogen burden with CMV, HSV-1, HSV-2 and/or H. pylori 
and all-cause/CVD-related mortality. The third aim will examine the association between 
seropositivity for specific combinations of pathogens and risk for all-cause/CVD-related mortality 
and assess the extent to which use of summed pathogen burden variables impact the ability of 
researchers to identify which particular pathogens, alone or in combination are most detrimental 
for health.  
The results of this research will benefit public health by clarifying the role of CMV, a 
persistent pathogen implicated in the etiology of numerous chronic diseases, inflammation and 
all-cause/CVD-related mortality. If CMV infection plays a strong role in the etiology of all-
cause/CVD-related mortality, particularly in conjunction with elevated CRP level, the elimination 
of CMV infection via the development and administration of treatments or vaccines and/or 
targeting the interaction of infection and CRP levels may reduce mortality rates in the United 
States. Furthermore, better understanding of the association between summed pathogen burden 
level and risk for all-cause/CVD-related mortality as well as the role of seropositivty for specific 
combinations of pathogens on determining risk for death will inform whether infection-related 
interventions should focus solely on reducing the crude number of pathogens individuals are 
exposed to or whether interventions focusing on the specific combinations of pathogens that are 
most detrimental to health would be more effective in reducing mortality in the U.S. general 
population. Thus, this work has important implications for future public health efforts designed to 






Chapter 2  
Seropositivity for Cytomegalovirus, Inflammation, All-cause and Cardiovascular Disease-related 
Mortality in the United States 
2.1 Background  
 Although a strong and consistent relation between psychological stress and 
Cytomegalovirus (CMV) is a highly transmissible and prevalent beta herpesvirus.
68,123
 This 
pathogen is never cleared from the body, persisting in a number of tissues via hypothesized 
mechanisms including chronic productive infection and/or latent infection with periodic subclinical 
reactivation.
68,69 
Recently, CMV has been linked to a variety of chronic diseases with an 





decline including vascular dementia 
38,74
 and functional impairment.
39,57,75
  
 Several mechanisms have been hypothesized to link CMV infection and CVD in both 
human and animal studies.
79,80,94,124-126
 CMV antigen and DNA have been identified in 
atherosclerotic vessels of the human cardiovascular system 
45,77,127
 and murine models suggest 
an inflammatory link with CVD progression.
125,126
 It has been hypothesized that CMV either 
directly infects the vessels of the heart and replicates at low levels, or is delivered to the vessel 
wall by infected circulating monocytes arriving at sites of cardiovascular injury or inflammation.
76
 
The presence of CMV in the vessel walls may induce smooth muscle cell proliferation and 
migration, increased uptake of oxidized low-density lipoprotein and expression of cytokines and 
chemokines as well as increased procoagulant activity by endothelial cells.
79-82
 CMV may also 
cause vascular damage without direct invasion as a result of molecular mimicry, whereby viral 
antigens trigger an immune response cross-reacting on self-peptides expressed on uninfected 
host tissues.
79,83,84
 For example, two CMV-derived proteins, UL122 and US28, are homologous to 
an amino acid sequence at position 153-160 of heat shock protein (HSP) 60.
85,86
 Thus, infection 
with CMV may contribute to progression of atherosclerosis and other CVD health outcomes via 
several mechanisms.  
 CMV has also been associated with other chronic diseases of aging, including physical 
impairment, cognitive decline and cancer.
38,39,57,72-75
  The specific mechanisms responsible for 
these associations have not been fully elucidated, but are likely to have an immune and 
inflammatory component.  Indeed, CMV seropositivity belongs to a cluster of immune factors 
constituting an “immune risk profile” associated with all-cause mortality at 2, 4 and 6-year follow-
up in elderly Swedes in the OCTO/NONA longitudinal studies.
128-131
 CMV is a driver of age-





naïve T cells available for fighting new infections.
131-134
 Reactivations or superinfections may 
result in higher titers of CMV immunoglobulin G (IgG) antibodies and increased levels of pro-
inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-
α).
50,87,88
 C-reactive protein (CRP) levels also increase as a consequence of reactivation or 
leakage of the virus from host cells, via the action of IL-6 produced in the liver.
80,89,90,135
 These 
inflammatory markers have been linked to both all-cause and CVD-related mortality.
118,136,137
 
Thus, CMV may impact both CVD-related and all-cause mortality through its affects on chronic 
inflammatory and immune-related changes seen with aging.  
 Although not all studies have supported a relationship between CMV and chronic disease 
outcomes,
138,139
 a majority of published studies have reported a significant relationship between 
CMV and mortality, in conjunction with markers of inflammation.
57-59,91,92
 A recent study by 
Roberts et al., examined the relationship between CMV antibody titer and all-cause/CVD mortality 
among elderly Latinos finding that subjects with CMV IgG antibody titers in the highest quartile 
had 1.43 (95% CI: 1.14, 1.79) times higher risk for all-cause mortality and 1.35 (95% CI: 1.01, 
1.80) times higher risk for CVD mortality in models adjusted for age, gender, education and 
comorbidity index. 
58
 The authors found the effect of CMV on mortality was partially mediated by 
a composite measure of two inflammatory markers, TNF-α and IL-6, but not CRP since it was 
unrelated to mortality in their study population.
58
 In contrast, Blankenberg et al. found CMV to be 
associated with cardiac mortality among persons with existing coronary artery disease (CAD) only 
in subjects with elevated IL-6 levels (hazard ratio (HR) 3.2, 95% confidence interval (CI): 1.4, 7.3) 
and not in those without IL-6 elevation, suggesting effect modification by IL-6 in the association 
between CMV and CVD-related mortality.
91
 Also examining the effect of CMV antibody titers on 
mortality, Strandberg et al. assessed 7-year risk for mortality in a small cohort of community-
dwelling 75-90 year-olds with underlying CVD in Finland.
59
 The authors found that mortality was 
significantly greater among subjects in the highest CMV IgG quartile, compared with the lowest 
quartile and that this association remained significant after controlling for several covariates 
including CRP, suggesting that CRP did not mediate this pathway.
59
 Furthermore, Muhlestein et 
al. examined the association between seropositivity to CMV, H. pylori and Chlamydia 
pneumoniae infections, as well as high CRP level and mortality among patients with a mean age 
of 65 years that were predominantly male and had angiographically demonstrated CAD.
92
 Of the 
three pathogens assessed, only seropositivity to CMV was significantly predictive of mortality. 
The authors also found that risk for mortality was greatest among CMV seropositive subjects with 
CRP levels in the highest tertile, suggesting a joint effect of CMV seropositivity and high CRP 
level on mortality among their sample of individuals with underlying CAD.
92
 
 Even though these studies suggest an association between CMV, inflammation and 
mortality, they were conducted in predominantly older age populations, of specific gender or 





conditions. While one cross-sectional study conducted among a U.S. population-based cohort of 
individuals aged 45 and older found that CMV was associated with reported history of CVD, it 
remains unclear whether a temporal relationship exists between CMV and mortality in the U.S. 
population.
40
 Moreover, the role of inflammatory markers such as IL-6, TNF-α and CRP as 
mediators or effect modifiers of the relationship between CMV and mortality is unclear.
57-59,91,92
  
Some studies support mediation by these markers, while others suggest effect modification.
57-
59,91,92
 Therefore, research examining whether inflammatory markers mediate or modify the 
relationship between CMV and mortality in the U.S. is needed.   
 The purpose of this study was to examine whether seropositivity for CMV predicts all-
cause as well as CVD-related mortality and whether CRP mediated or modified these 
relationships in a nationally representative U.S. population of individuals aged 25 and older. 
2.2 Methods  
Study population 
 Data come from the National Health and Nutrition Examination Survey (NHANES) III 
(1988–1994), a population-based, multistage stratified probability survey which collects 
information on the health and nutrition of the United States civilian non-institutionalized 
population. The survey was carried out by the National Center for Health Statistics (NCHS), 
Centers for Disease Control and Prevention and is meant to be representative of the U.S. 
population. In addition, we used data from the NHANES III-Linked Mortality file in which the 
mortality status of NHANES III participants was determined by probabilistic matching between 
NHANES III participants and the U.S. National Death Index (NDI).
140
 
  A total of 33994 subjects were interviewed in NHANES III. Our study sample is limited to 
subjects that were 25 years of age and older (range 25-90 years of age) at time of examination 
(N=15242 (48.7%)), were tested for CMV serostatus and CRP level (N=14164 (92.9%)) and 
eligible for mortality follow-up on December 31st, 2006 (N=14153 (99.9%). Forty-eight subjects 
(0.3%) were excluded from the analyses of CVD-related mortality because their cause of death 
could not be ascertained.  
Laboratory Analyses 
 CMV-specific IgG was measured by a commercially available Enzyme Linked 
Immunosorbent Assay (ELISA) (Quest International, Inc., Miami, FL). Sera with values near the 
ELISA cutoff were confirmed with a second ELISA assay (bioMerieux, Inc., Durham, NC). If the 
results from the first two tests disagreed, an Immunofluorescence Assay (IFA) (Bion International, 
Inc., Park Ridge, IL), was used and results from this test were provided as the final seropositivity 
test result. The sensitivity and specificity of these tests have been estimated to be 98% and 99%, 
respectively.
67, 141
 Although CMV IgG and IgM antibody titer levels are available in NHANES III, 






 Sera collected for the purpose of CRP testing were stored at -70 C and analyzed within 2 
months using a modification of the Behring Latex-Enhanced CRP assay on the Behring 
Nephelometer Analyzer system™ (Behring Diagnostics, Westwood, MA). Both within and 
between-assay quality control procedures were used and the coefficient of variation was 3.2%-
16.1% through the period of data collection. The limit of detection for CRP was 0.3 mg/dL.
142
  
Sera collected for the purpose of cholesterol testing were frozen and stored at -20 C, then 
shipped on dry ice within four weeks to the Johns Hopkins University Lipid Research Clinic 
Laboratory which participates in the Lipid Standardization Program of the Centers for Disease 
Control and Prevention. Total cholesterol was measured enzymatically on a Hitachi 717 analyzer 





 Results from the CMV IgG antibody tests were dichotomized as seronegative or 
seropositive based on the ELISA results. Results from the CRP tests were dichotomized as low: 
< 0.3 mg/dL and high: ≥ 0.3 mg/dL according to commonly used cut-off values thought to have 
clinical significance for prediction of heart attack or stroke.
143
 Combined CMV serostatus and 
CRP level was categorized as CMV seronegative/low CRP, CMV seronegative/high CRP, CMV 
seropositive/low CRP and CMV seropositive/high CRP. 
 Mortality status was obtained primarily from the NDI; however, other sources of mortality 
status included indication of deceased status from the Social Security Administration, the Centers 
for Medicare and Medicaid Services, or death certificate review.
140
 Cause of death was coded 
using the International Classification of Diseases, Ninth Revision (ICD-9) up until 1998 and ICD-
10 for 1999-2006. All deaths before 1999 were recoded by the NCHS into comparable ICD-10 
codes.
144
 ICD-10 codes I00-I99 were classified as CVD-related deaths and included, causes of 
death such as hypertensive heart disease, atherosclerosis including coronary and 
cerebrovascular disease, heart failure, and aortic aneurysms. Persons who survived the entire 
follow-up period were administratively censored on December, 31st 2006. Follow-up time for 
each person was calculated as the difference between the NHANES III examination date and the 
last known date alive or censored.
144
 Persons who died of non-CVD causes were considered 
censored at the date of death for CVD mortality analysis. 
 Covariates hypothesized to be potential confounders of the relationship between CMV 
serostatus and mortality included age, gender, race/ethnicity, country of origin, body mass index 
(BMI) (kg/m
2
), smoking status, diabetes status and education level, because these factors have 
been shown to predict both risk for infection and mortality.
23, 67,145-148
 Age in years at examination 
was self-reported and treated as a continuous variable. Gender was dichotomized as female and 
male. Race/ethnicity was self-reported as non-Hispanic white, non-Hispanic black, Mexican-





subjects were born and was categorized as U.S. or Other. Education level was chosen as a 
marker of life course socioeconomic position most likely to precede CMV infection and self-




) was computed from 
weight and standing height and categorized as BMI < 25, 25 ≤ BMI < 30 and BMI ≥ 30. Smoking 
status was self-reported and categorized into never (did not smoke 100+ cigarettes in one‟s 
lifetime), past (smoked 100+ cigarettes in one‟s lifetime but do not currently smoke) and current 
smoker (smoked 100+ cigarettes in one‟s lifetime and currently smoke). Diabetes was self-
reported as whether a doctor ever informed subjects they had diabetes or not and dichotomized 
as reported or not reported.  In addition, use of non-steroidal anti-inflammatory drugs (NSAID) 
was hypothesized as a confounder in the association between the combined effect of CMV 
serostatus/CRP level and mortality.
151,152
  Subjects were considered to use NSAIDs if they 
reported use of prescription drugs in the past month with a primary classification of NSAID 
according to the Product Information Branch, Center for Drug Evaluation and Research at the 
U.S. DHHS Food and Drug Administration or if subjects self-reported taking any Advil, Nuprin, 
Medipren or Ibuprofen in the past month.
153
 
 Total serum cholesterol and hypertension were hypothesized as mediators in the 
pathway between the combined effect of CMV serostatus/CRP level and CVD-related mortality. 
Serum total cholesterol level was dichotomized as low (< 240 mg/dL) and high (≥ 240 mg/dL) 
according to the National Cholesterol Education Program Expert Panel 
154
 and hypertension was 
reported as ever having been told by a doctor or health professional that you had hypertension, 
also called high blood pressure. 
Statistical analyses 
 Statistical analyses were performed using SAS, version 9.2, with SAS-callable SUDAAN, 
version 10.0.1 (SAS Institute, Inc., Cary, NC).
155
 All analyses used appropriate weights and 
adjustments for strata and clustering used in the complex study design used in NHANES III. 
Bivariate relationships between CMV serostatus, CRP level, all-cause and CVD-related mortality 
and potential confounders including age, gender, race/ethnicity, country of origin, education level, 
BMI (kg/m
2
), smoking status, diabetes status and NSAID use were assessed. Covariates were 
considered confounders based on a priori hypotheses and if they were associated with the 
exposure and associated with the outcome among the unexposed.
156
 T-tests (two-tailed) for 
difference in means and Pearson chi-square tests of independence for proportions and test for 
trend among demographic groupings were calculated.  
 Kaplan-Meier survival curves were plotted for all-cause and CVD-related mortality by 
CMV serostatus to examine the unadjusted association between CMV serostatus and all-
cause/CV-related mortality. Survival time was measured in months since mobile or home 
examination. Cox proportional hazard models were used to estimate the confounder adjusted HR 





in models adjusted for sociodemographic factors (age, gender, race/ethnicity, country of origin 
and education level), then, in models additionally adjusted for clinical factors (BMI (kg/m
2
), 
smoking status and diabetes status and last in models also controlling for CRP level. In order to 
assess whether CRP level mediated the relationship between CMV and mortality we compared 
the HR for all-cause and CVD-related mortality, before and after controlling for CRP in the fully 
adjusted model. Adjusted Wald F statistics were estimated to compare follow-up time in months 
from exam to death between those CMV seronegative versus CMV seropositive in fully adjusted 
models. 
 To assess whether CRP modified the relationship between CMV and all-cause/CVD-
related mortality we first examined the crude association between combined CMV serostatus and 
CRP level by plotting unadjusted Kaplan-Meier survival curves for all-cause and CVD-related 
mortality by combined CMV serostatus and CRP level over the follow-up period. Survival time 
was measured in months since mobile or home examination. Next we used Cox proportional 
hazard models to estimate the confounder adjusted HR and 95% CI for the association between 
CMV serostatus/CRP level and all-cause/CVD-related mortality first in models adjusted for 
sociodemographic factors (age, gender, race/ethnicity, country of origin and education level) and 
second, in models adjusted for clinical factors (BMI (kg/m
2
), smoking status, diabetes status and 
NSAID use). Last, adjusted Wald F statistics were estimated to compare follow-up time in months 
from exam to death between each combination of CMV serostatus and CRP level, adjusting for 
covariates.  
 To examine whether more proximal risk factors for CVD, including total cholesterol level 
and hypertension, lie in the pathway between the combined effect of CMV seropositivity/high 
CRP level and CVD-related mortality, we compared the HR for CVD-related mortality for those 
CMV seropositive with high CRP level to individuals that were CMV seronegative with low CRP 
level, before and after controlling for these factors. 
2.3 Results 
 Weighted estimates of the bivariate relationships between covariates of interest and CMV 
serostatus are shown in Table 2.1. The weighted proportion of those seropositive to CMV was 
66.7%. Higher mean age, female gender, non-white race/ethnicity, country of origin outside the 
U.S., lower mean education level, low BMI (< 25 kg/m2) and high BMI (≥ 30 kg/m
2
) compared to 
medium BMI (25 ≤ BMI < 30), reported diabetes and high CRP level (≥ 0.3 mg/dL) were 
associated with CMV seropositivity. Although hypothesized as a potential confounder in the 
association between CMV serostatus and mortality, smoking status was not associated with CMV 
serostatus in our study. During the mean 13.7 years of follow-up from exam, the population 
estimate for the proportion dying from all causes was 18.9% and the proportion dying from CVD-
related mortality was 8.0%.  





Table 2.1 Demographic and Clinical Characteristics (Weighted) by Cytomegalovirus 
Serostatus Among Subjects Aged 25 and Older in NHANES III.     
  CMV Serostatus  (N=14153)  
  Seronegative Seropositive  
 33.3% 66.7%  
Covariate    p-value 
Age (Years at Examination) (Mean ± SE)                  41.3 ± 0.43 51.1  ± 0.51 <.0001* 
Gender    
Female 44.3% 56.1% <.0001* 
Male 55.7% 43.9%  
Race/Ethnicity    
Non-Hispanic White 91.7% 71.0% <.0001* 
Non-Hispanic Black 4.1% 13.1%  
Mexican-American 1.6% 6.2%  
Other 2.6% 9.7%  
Country of Origin
†
    
United States 95.7% 82.1% <.0001* 
Other 4.3% 17.9%  
Education Level (Years)
‡
 (Mean ± SE) 13.5 ± 0.09 11.8  ± 0.09 <.0001* 




    
≤ 24.9 45.4% 40.8% .0317* 
25-29.9 32.6% 34.9%  
≥30 22.0% 24.3%  
Smoking Category    
Never smoker 44.8% 44.1% .9221 
Former smoker 26.8% 28.4%  
Current smoker 28.4% 27.5%  
Diabetes
§
    
No 96.0% 93.0% <.0001* 
Yes 4.0% 7.0%  
C-reactive Protein Level    
Low (< 0.3 mg/dL) 76.1% 67.0% <.0001* 
High (≥ 0.3 mg/dL) 23.9% 33.0%  
*Significant at p<0.05, t-tests for difference in means and Pearson chi-square tests for  
differences in proportions or test for trend among demographic groupings were calculated. 
†
N=14114 due to 39 subjects missing data on country of origin. 
‡ 
N=14059 due to 94 subjects missing data on education level. 
±




N=14139 due to 14 subjects missing data on diabetes status. 
 
 The unadjusted Kaplan-Meier survival curves for all-cause mortality by CMV serostatus 
are shown in Figures 2.1 and 2.2 below. Overall mean survival duration since time of exam for 
those CMV seropositive was 13.4 years (160.4 ± 2.40 months) whereas mean survival duration 






Figure 2.1 Kaplan-Meier Survival Curve for All-Cause Mortality by Cytomegalovirus 
Serostatus. Unadjusted Kaplan-Meier survival curves for all-cause mortality by cytomegalovirus 
(CMV) serostatus for 14153 subjects, ≥ 25 years of age, in the National Health and Nutrition 
Examination Survey (NHANES) III from 1988-2006. After adjusting for age, gender, race/ethnicity, 
country of origin, education level, body mass index (kg/m
2
), smoking status and diabetes status, 
follow-up time from exam to death from all causes was significantly different between CMV 








Figure 2.2 Kaplan Meier Survival Curve for Cardiovascular Disease-related Mortality by 
Cytomegalovirus Serostatus. Unadjusted Kaplan-Meier survival curves for cardiovascular 
disease (CVD)-related mortality by cytomegalovirus (CMV) serostatus for 14105 subjects, ≥ 25 
years of age, in the National Health and Nutrition Examination Survey (NHANES) III from 1988-
2006. After adjusting for age, gender, race/ethnicity, country of origin, education level, body 
mass index (kg/m2) , smoking status and diabetes status, follow-up time from exam to death 
from CVD was not significantly different between CMV seronegative and CMV seropositive 










 Table 2.2 shows the HR and 95% CI from Cox proportional hazard models examining the 
association between CMV and all-cause/CVD-related mortality, mutually adjusted for 
hypothesized confounders. After adjusting for age, gender, race/ethnicity, country of origin, 
education level, BMI (kg/m
2
), smoking status and diabetes status, CMV seropositivity remained 
statistically significantly associated with all-cause mortality (HR 1.19, 95% CI: 1.01, 1.41) and 
follow-up time from exam to death from all causes was significantly different between CMV 
seronegative and CMV seropositive subjects (Adjusted Wald F = 4.66, p-value = 0.0358) in model 
2. The effect of CMV on all-cause mortality was not further attenuated after controlling for CRP 
level (HR 1.19, 95% CI: 1.01, 1.40 versus HR 1.19, 95% CI: 1.01, 1.41). Although the magnitude 
of effect for CVD-related mortality was similar to that of all-cause mortality, the association 
between CMV and CVD-related mortality was not statistically significant in the fully adjusted 
model and follow-up time from exam to death from CVD-related mortality for those CMV 
seropositive versus seronegative was not statistically significantly different (Adjusted Wald F = 
2.66, p-value = 0.1092). Similarly, adjustment for CRP level did not further attenuate the 
association between CMV and CVD-related mortality (HR 1.19, 95% CI: 0.95, 1.49 versus HR 














Table 2.2 The Relationship Between Cytomegalovirus Serostatus, C-reactive Protein Level and All-Cause/Cardiovascular Disease-
related Mortality in Subjects 25 Years of Age and Older in NHANES III 
 Hazard Ratio ( 95% Confidence Interval) 














CMV       
Seronegative 1.0 1.0 1.0 1.0 1.0 1.0 
Seropositive 1.20 (1.03, 1.41)* 1.19 (1.01, 1.41)* 1.19 (1.01, 1.40)* 1.20 (0.96, 1.50) 1.19 (0.96, 1.49) 1.19 (0.95, 1.49) 
Age   
(years since 
exam) 
1.09 (1.09, 1.10)* 1.10 (1.09, 1.11)* 1.10 (1.09, 1.10)* 1.11 (1.11, 1.12)* 1.12 (1.11, 1.13)*  1.12 (1.11, 1.13)* 
Gender       
Female 1.0 1.0 1.0 1.0 1.0 1.0 
Male 1.49 (1.35, 1.64)* 1.40 (1.27, 1.54)* 1.42 (1.29, 1.57)* 1.58 (1.39, 1.80)* 1.54 (1.34, 1.77)* 1.57 (1.36, 1.80)* 
Race/Ethnicity       
Non-Hispanic 
White 
1.0 1.0 1.0 1.0 1.0 1.0 
Non-Hispanic 
Black 
1.27 (1.12, 1.45)* 1.20 (1.05, 1.37)* 1.17 (1.03, 1.33)* 1.20 (1.00, 1.44) 1.11 (0.92, 1.35) 1.09 (0.90, 1.30) 
Mexican-
American 
0.88 (0.74, 1.05) 0.88 (0.74, 1.05) 0.87 (0.73, 1.03) 0.89 (0.67, 1.17) 0.86 (0.66, 1.13) 0.85 (0.65, 1.12) 
Other 0.83 (0.64, 1.07) 0.76 (0.59, 0.99)* 0.78 (0.60, 1.01) 0.88 (0.53, 1.47) 0.78 (0.45, 1.35) 0.80 (0.47, 1.37) 
Country of 
Origin 
      
United States 1.0 1.0 1.0 1.0 1.0 1.0 










      








*Significant at p<0.05 
†
Model 1 for all-cause mortality (N=14029) and for cardiovascular disease-related mortality (N=13981) adjusted for age, gender, race/ethnicity, 
country of origin and education level and reduced by 124 subjects due to missing data on country of origin and/or education level. 
‡
 Model 2 for all-cause mortality (N=13981) and for cardiovascular disease-related mortality (N=13934) adjusted for age, gender, race/ethnicity, 
country of origin, education level, body mass index (kg/m
2
), smoking status and/or diabetes status. Model 2 for all-cause mortality reduced by an 
additional 48 subjects and for cardiovascular disease-related mortality reduced by an additional 47 subjects due to missing data on body mass 
index, smoking status and/or diabetes status.  
¶ 
Model 3 for all-cause mortality (N=13981) and for cardiovascular disease-related mortality (N=13934) adjusted for age, gender, race/ethnicity, 
country of origin, education level, body mass index (kg/m
2
), smoking status, diabetes status and C-reactive protein level. 
 
 
25 ≤ BMI < 30 ---- 1.0 1.0 ---- 1.0 1.0 
≥ 30 ---- 1.21 (1.05, 1.40)* 1.16 (1.00, 1.33) ---- 1.34 (1.08, 1.66)* 1.28 (1.03, 1.58)* 
Smoking 
Status 
      
Never ---- 1.0 1.0  1.0 1.0 
Former ---- 1.28 (1.14, 1.44)* 1.27 (1.13, 1.42)*  1.16 (1.00, 1.35) 1.15 (1.00, 1.33) 
Current ---- 2.27 (2.00, 2.58)* 2.20 (1.93, 2.50)*  1.96 (1.62, 2.37)* 1.90 (1.58, 2.29)* 
Diabetes       
No ---- 1.0 1.0 ---- 1.0 1.0 
Yes ---- 1.90 (1.65, 2.19)* 1.87 (1.63, 2.15)* ---- 1.99 (1.62, 2.46)* 1.96 (1.60, 2.42)* 
C-reactive 
Protein Level 
      
Low (< 0.3 
mg/dL) 
---- ---- 1.0 ---- ---- 1.0 
High (≥ 0.3 
mg/dL) 






 Figures 2.3 and 2.4 show the unadjusted Kaplan-Meier survival curves for all-cause and CVD-
related mortality by the four different permutations of CMV serostatus and CRP level. The overall mean 
survival times from exam to mortality for each combination of CMV serostatus and CRP level were 14.7 
years (176.0 ± 3.20 months) for CMV seronegative individuals with low CRP, 13.8 years (165.6 ± 3.49 
months) for CMV seronegative individuals with high CRP, 13.8 years (165.5 ± 2.46 months) for CMV 
seropositive individuals with low CRP and 12.5 years (150.0 ± 3.49 months) for CMV seropositive 
individuals with high CRP. 
 
Figure 2.3 Kaplan-Meier Survival Curve for All-Cause Mortality by Combined 
Cytomegalovirus Serostatus and C - reactive protein Level.  Unadjusted Kaplan-Meier 
survival curves for all-cause mortality by combined cytomegalovirus (CMV) serostatus and C-
reactive Protein (CRP) level for 14011 subjects, ≥ 25 years of age, in the National Health and 
Nutrition Examination Survey (NHANES) III from 1988-2006. After adjusting for age, gender, 
race/ethnicity, country of origin, education level, BMI (kg/m
2
), smoking status, diabetes status and 
non-steroidal anti-inflammatory drug use, follow-up time from exam to death from all-causes for 





seropositive individuals with low CRP level (Adjusted Wald F = 36.19, p<0.0001). 
CMV=cytomegalovirus, CRP=C - reactive protein. High CRP level: ≥ 0.3 mg/dL. 
 
 
Figure 2.4 Kaplan Kaplan-Meier Survival Curve for Cardiovascular Disease-Related 
Mortality by Combined Cytomegalovirus Serostatus and C - reactive protein Level. 
Unadjusted Kaplan-Meier survival curves for cardiovascular disease (CVD)-related mortality by 
combined cytomegalovirus (CMV) serostatus and C-reactive Protein (CRP) level for 13963 
subjects, ≥ 25 years of age, in the National Health and Nutrition Examination Survey (NHANES) 
III from 1988-2006. After adjusting for age, gender, race/ethnicity, country of origin, education 
level, BMI (kg/m
2
), smoking status, diabetes status and non-steroidal anti-inflammatory drug use, 
follow-up time from exam to CVD-related death for CMV seropositive individuals with high CRP 
level was significantly different from CMV seropositive individuals with low CRP level (Adjusted 








Table 2.3 shows the HR and 95% CI from Cox proportional hazard models examining the 
association between different permutations of CMV serostatus and CRP level and all-cause or 
CVD-related mortality, adjusted for confounders. After adjustment for age, gender, race/ethnicity, 
country of origin, education level, BMI (kg/m
2
), smoking status, diabetes status and NSAID use, 
the highest HR for all-cause and CVD-related mortality was found among people who were both 
CMV seropositive and had high CRP levels (HR 1.60, 95% CI: 1.31, 1.94, and HR 1.71, 95% CI: 
1.21, 2.42, respectively), compared to CMV seronegative subjects with low CRP. Thus, even after 
confounder adjustment, subjects that were CMV seropositive and had high CRP had a 30.1% 
higher risk for all-cause mortality and 29.5% higher risk for CVD-related mortality compared to 
CMV seropositive subjects who had low CRP levels. The follow-up time from exam to death from 
all-causes for CMV seropositive individuals with high CRP was significantly different from CMV 
seropositive individuals with low CRP (Adjusted Wald F = 36.19, p<0.0001) in fully adjusted 
models. In addition, the follow-up time from exam to CVD-related death for CMV seropositive 
individuals with high CRP was significantly different from CMV seropositive individuals with low 
CRP (Adjusted Wald F = 9.10, p = 0.0040) in fully adjusted models. After adjustment for total 
cholesterol level and hypertension, the HR for CVD-related mortality among those CMV 
seropositive with high CRP level compared to individuals that were CMV seronegative with low 


























*Significant at p<0.05 
†
Model 1 for all-cause mortality (N=14029) and for CVD-related mortality (N=136981) adjusted for age, gender,  
race/ethnicity, country of origin and education level and reduced by 124 subjects due to missing data on country of origin  
and/or education level. 
‡
Model 2 for all-cause mortality (N=13611) and for CVD-related mortality (N=13569) adjusted for age, gender,  
race/ethnicity, country of origin, education level, body mass index (kg/m
2
), smoking status, diabetes status and  
non-steroidal anti-inflammatory drug use. Model 2 for all-cause mortality reduced by an additional 418 subjects and model 
2 for CVD-related mortality reduced by an additional 322 subjects due to missing data on body mass index, smoking status,  







Table 2.3 The Combined effect of Cytomegalovirus (CMV) Serostatus and C-reactive Protein (CRP) Level on All-
Cause/Cardiovascular Disease (CVD) -related Mortality in Subjects 25 Years of Age and Older in NHANES III 
 
 Hazard Ratio (95% Confidence Interval) 
 All-Cause Mortality CVD-related Mortality 









CMV Seronegative and Low CRP Level 1.0 1.0 1.0 1.0 
CMV Seronegative and High CRP Level 1.56 (1.23, 1.97)* 1.46 (1.16, 1.83)* 1.81 (1.17, 2.78)* 1.67 (1.08, 2.57)* 
CMV Seropositive and Low CRP Level 1.25 (1.04, 1.49)* 1.23 (1.03, 1.47)* 1.33 (0.97, 1.81)         1.32 (0.97, 1.78) 







This study examined whether seropositivity for CMV, an indicator of prior infection with 
this persistent herpesvirus, predicts all-cause as well as CVD-related mortality and whether CRP 
mediates or modifies this relationship in a nationally representative U.S. population of individuals 
25 years of age and older. The results of our study suggest that CMV seropositivity is 
independently associated with all-cause mortality, after controlling for age, gender, race/ethnicity, 
country of origin, education level, BMI (kg/m
2
), smoking status and diabetes status. Furthermore, 
adjustment for CRP level did not attenuate this relationship.  
After confounder adjustment, CMV serostatus was no longer significantly associated with 
CVD mortality. It is possible that the strong relationship between CMV and all-cause mortality 
observed in this study indicates that CMV seropositive subjects are dying of competing causes 
before they have the chance to develop CVD, attenuating the relationship between CMV and 
CVD-related mortality. High levels of CRP, however, augmented the effect of CMV seropositivity 
on both all-cause and CVD-related mortality. Among CMV seropositive subjects, those with high 
CRP levels showed approximately a 30% higher risk for all-cause mortality and for CVD-related 
mortality, compared to those with low CRP levels. Adjusting for CVD risk factors such as high 
total cholesterol and hypertension resulted in a moderate attenuation (decrease of 3.5%) of the 
association between combined CMV seropositivity and high CRP level and CVD-related mortality, 
supporting the hypothesis that CMV seropositivity along with subclinical inflammation impacts risk 
for mortality in part through their combined contribution to other more proximal CVD risk factors. 
Nonetheless, these markers of CVD did not completely attenuate the association, indicating that 
other factors may also be on the pathway or that there is a direct relationship between CMV 
infection, CRP levels and CVD-related mortality. Thus, our research suggests that efforts 
identifying the mechanisms of these additive effects and targeted CVD intervention studies 
among subpopulations with these biomarker risk profiles are warranted. 
It has been suggested that individuals who are CMV seropositive and also have a 
subclinical inflammatory profile are more susceptible to the atherogenic effects of CMV infection, 
whereas those without a subclinical response are not as susceptible.
92,135
 Studies support a 
correlation between increased CRP and increased CMV antibody titers- a marker of reactivation - 
but the directionality among these two biological markers is unclear.
58,59,157
  If elevated CRP is a 
marker of “reactivating” CMV infection, whereas low CRP indicates resolved or “latent” CMV 
infection, we would expect CRP levels to be increased during times of CMV reactivation and for 
CMV infection to be most detrimental under these circumstances. Since CMV has been found to 
directly invade cardiovascular tissues
45,77,127
 periods of CMV “reactivation” may accelerate the 
atherogenic process by increasing the detrimental effects of tissue invasion such as smooth 
muscle cell proliferation and migration.
79-82
 On the other hand, if, as hypothesized, molecular 






may become hyper-stimulated during periods of CMV “reactivation” leading to an exacerbated 
attack against host tissues presenting cross-reacting human peptides.
83-86
  For these reasons, the 
greatest physiological harm caused by CMV is likely to occur during “reactivation” events, 
possibly at a subclinical level. If subclinical “reactive” CMV infection is most important in the 
etiology of mortality, then situations that cause CMV reactivation over the lifecourse, such as 
stress, inflammation caused by co-infections, immunosuppression and aging may play important 
key roles in determining the extent to which CMV infection is detrimental to health. 
Although CMV IgG and IgM antibody titer levels are available in NHANES III, values for 
subjects over age 49 were top-coded, making them unusable as a predictor of mortality. It was 
also not possible to correlate antibody levels as an indicator of “reactivating” versus “latent” CMV 
infection in our study population. In addition, approximately 64% of our study population had CRP 
levels under the limit of detection (< 0.3 mg/dl), because more sensitive assays that are currently 
available for measurement of high-sensitivity CRP below this limit of detection were not used in 
NHANES III, making it difficult to examine CRP levels continuously. Therefore, one limitation of 
our study is that were unable to examine the relationship between CMV antibody titer and CRP 
level more closely, which might have allowed us to identify a more precise interaction between 
CMV infection and CRP levels and their effect on all-cause and CVD-related mortality. Another 
limitation associated with using CRP as a predictor of mortality is that very high values of CRP 
may represent acute infection or injury not necessarily associated with cardiovascular disease. In 
addition, the causal relations and therapeutic implications pertaining to CRP and CVD are 
currently unclear.
158-161
 However, other inflammatory markers that have been shown to play a 
significant role in the pathway between CMV and mortality, such as IL-6, are not available in 
NHANES III. Thus, it was not possible to determine whether other inflammatory markers in 
addition to CRP mediate or modify the relationship between CMV and mortality. Nonetheless, our 




Another limitation to our study is that we utilized the updated NHANES III Linked Mortality 
Public-use File which was subject to data perturbation in which synthetic data was substituted for 
the actual date of death and underlying cause of death for selected descendent records in order 
to reduce risk of respondent re-identification.
162
 Despite the data perturbation of date of death for 
selected decedents in the public-use file, a comparison study between the public-use and 
restricted-use file (which does not contain perturbed data) conducted by the NCHS, found that 
analysis of all-cause and cause-specific mortality (heart disease, ischemic heart disease and 
cerebrovascular disease, in particular) by sociodemographic factors including as age, sex, 
race/ethnicity and education level to be comparable across files and concluded that the 
discrepancies between the public-use and restricted-use file were minor and that analysts should 
use the public-use file with confidence.
162






two sources (National Death Index (NDI) and/or death certificate review.
140
 Furthermore, NDI is a 





Several studies have examined the relationship between CMV and mortality.
57-59, 91, 92
 
However, these earlier studies have only examined the relationship among specific gender and 
racial/ethnic subgroups, often among subjects with existing CVD and primarily compared 
mortality by CMV antibody titer level (not CMV serostatus). To the best of our knowledge, our 
study is the first to utilize a large, nationally representative U.S. population aged 25 and older with 
up to 18.1 years of follow-up (mean of 13.7 years) to examine the relationship between CMV 
serostatus, CRP level and all-cause/CVD-related mortality. Therefore, the population studied here 
is much broader in age and on average younger than the study populations utilized in several 
earlier studies examining the impact of CMV infection on mortality. A moderate increase in risk 
among a large population with a wide age range in the US has important implications for 
potentially shifting the population burden of diseases.
164
 
If CMV infection plays a strong role in the etiology of all-cause and CVD-related mortality 
in conjunction with high CRP level, the elimination of CMV infection via the development and 
administration of treatments or vaccines 
164
 and/or targeting the interaction of infection and CRP 
levels may reduce mortality rates in the United States. Colugnati et al. predicted that a 
vaccination against CMV would not need to have high efficacy nor wide-spread coverage to make 
a substantial impact on CMV transmission and elimination of CMV from the population has the 
potential to greatly reduce the incidence of disease attributable to CMV infection.
40, 165
 Therefore, 
elimination of CMV infection is a potentially feasible and important avenue of study for preventing 









Chapter 3  
Summed Pathogen Burden and Risk for All-Cause and Cardiovascular Disease-related Mortality 
in the United States 
3.1 Background 
Over the past 30 years, a growing body of evidence has implicated numerous individual 
pathogens, both viral and bacterial species, in cardiovascular disease (CVD) 
40,43,166
 as well as 





 and cognitive impairment 
38,167
 and cancer. 
72,73,93,110
 Persistent pathogens are linked 
to chronic disease via direct, pathogen-specific effects such as in the case of CVD, in which 
certain pathogens invade vascular tissues and trigger atherogenesis.
46,79,124,127
 In addition, initial 
infection as well as reactivation with persistent pathogens triggers the release of acute phase 
proteins and increases levels of inflammatory markers such as C-reactive protein, which have 
been linked to CVD and other chronic diseases.
50-56
  As a result, it has been hypothesized that 
due to an accumulation of both pathogen-specific effects, as well as overall increased levels of 
inflammation, the more pathogens an individual is seropositive for (i.e., increased summed total 
pathogen burden), the greater their risk for chronic disease and mortality.
52,54,84,168-171
  
Despite the hypothesized relationship between summed pathogen burden, inflammation 
and chronic disease, very few studies have examined the association between summed 
pathogen burden and mortality.
60-62,119
 The few studies that exist were primarily conducted among 
persons with existing CVD, of older age and from specific race/ethnic groups limiting their 
generalizability to the general population.
60-62,119
 Therefore, the objective of this study is to 
examine whether there is a graded relationship between increasing pathogen burden with four 
persistent pathogens (cytomegalovirus (CMV), herpes simplex virus-1(HSV-1), herpes simplex 
virus-2 (HSV-2) and/or Helicobacter pylori (H. pylori)) implicated in CVD as well as other chronic 
diseases with inflammatory etiology
38,41,44,46,74,93,172-174
 and all-cause/CVD-related mortality in a 
U.S. representative population of individuals ≥ 25 years of age. 
3.2 METHODS 
Study population 
 Data come from the National Health and Nutrition Examination Survey (NHANES) III 
(1988–1994); a population-based, multistage stratified probability survey which collected 
information on the health and nutrition of the United States civilian non-institutionalized 
population. The survey was carried out by the National Center for Health Statistics (NCHS), 






NHANES III, but our study sample is limited to subjects who were 25 years of age and older at 
time of examination (N=15242 (48.7%)), had mortality follow-up (N=15229 (99.9%)) and were 
tested for serostatus for all four pathogens (N=6522 (42.8%)). Sera was selected randomly for 
seropositivity testing, however, only subjects in phase I were tested for H. pylori, therefore, our 
analysis was limited to subjects tested for seropositivity for the other three pathogens in phase I. 
In addition, we used data from the NHANES III-Linked Mortality file in which the mortality status of 
NHANES III participants was determined by probabilistic matching between NHANES III 
participants and the U.S. National Death Index (NDI).
140
 Cause of death was unavailable for 18 
subjects, thus, these subjects were excluded from analysis for CVD-related mortality.  
Laboratory Analyses 
CMV-specific IgG was measured by a commercially available Enzyme Linked 
Immunosorbent Assay (ELISA) (Quest International, Inc., Miami, FL). Sera with values near the 
ELISA cutoff were confirmed with a second ELISA assay (bioMerieux, Inc., Durham, NC). If the 
results from the first two tests disagreed, an Immunofluorescence Assay (IFA) (Bion International, 
Inc., Park Ridge, IL), was used and results from this test were provided as the final seropositivity 
test result. The sensitivity and specificity of these tests have been estimated to be 98 and 99%, 
respectively.
67,141
 HSV-1 and HSV-2 seropositivity was assessed by solid-phase enzymatic 
immunodot assays using purified glycoprotein gG-1 of HSV-1 and gG-2 of HSV-2 as the 
antigen.
175
 These immunodot assays have also been shown to have high sensitivity and 
specificity.
176
 Subjects 20 years and older from phase 1 (1988-1991) were tested for H. Pylori 
antibody in 1996 using H. Pylori IgG ELISA (Wampole Laboratories, Cranbury, NJ). The cut 
points for seropositivity to each infection are based on commercially available immunoassay 




Results from the IgG antibody tests for each pathogen were dichotomized as 
seronegative or seropositive based on the ELISA results. Summed pathogen burden was 
constructed as the total number of pathogens for which each subject was seropositive (range 0-
4), producing 5 pathogen burden levels, with seropositivity for zero pathogens serving as the 
referent category. 
Mortality status was obtained by NCHS primarily from the National Death Index (NDI); 
however, other sources of mortality status included indication of deceased status from the Social 
Security Administration, the Centers for Medicare and Medicaid Services, or death certificate 
review.
140
 Cause of death was coded using the International Classification of Diseases, Ninth 
Revision (ICD-9) up until 1998 and ICD-10 for 1999-2006. All deaths before 1999 were recoded 
by the NCHS into comparable ICD-10 codes.
144
 ICD-10 codes I00-I99 were classified as CVD-
related deaths and included, causes of death such as hypertensive heart disease, atherosclerosis 






who survived the entire follow-up period were administratively censored on December, 31
st
 2006. 
Follow-up time for each person was calculated in months as the difference between the NHANES 
III examination date and the last known date alive or censored.
144
 Persons who died of non-CVD 
causes were considered censored at the date of death for CVD mortality analysis. 
Covariates hypothesized to be potential confounders of the relationship between 
summed pathogen burden and mortality included age, gender, race/ethnicity, country of origin, 
body mass index (BMI) (kg/m
2
), smoking status, diabetes status and education level, because 
these factors have been shown to predict both risk for infection and mortality.
23, 67,145-148
 Age in 
years at examination was self-reported and treated as a continuous variable. Gender was 
dichotomized as female and male. Race/ethnicity was self-reported as non-Hispanic white, non-
Hispanic black, Mexican-American or Other. Country of origin was reported as the state or foreign 
country in which subjects were born and was categorized as U.S. or Other. Education level was 
chosen as a marker of life course socioeconomic position most likely to precede CMV infection 





computed from weight and standing height and categorized as BMI < 25, 25 ≤ BMI < 30 and BMI 
≥ 30. Smoking status was self-reported and categorized into never (did not smoke 100+ 
cigarettes in one‟s lifetime), past (smoked 100+ cigarettes in one‟s lifetime but do not currently 
smoke) and current smoker (smoked 100+ cigarettes in one‟s lifetime and currently smoke). 
Diabetes was self-reported as whether a doctor ever informed subjects they had diabetes or not 
and dichotomized as reported or not reported.  
Statistical analyses 
Statistical analyses were performed using SAS, version 9.2, with SAS-callable SUDAAN, 
version 10.0.1 (SAS Institute, Inc., Cary, NC).
155
 All analyses used appropriate weights and 
adjustments for strata and clustering used in the complex study design in NHANES III. Bivariate 
relationships between summed pathogen burden and all-cause/CVD-mortality and survival 
duration as well as between summed pathogen burden and potential confounders including age, 
gender, race/ethnicity, country of origin, education level, BMI (kg/m
2
), smoking status and 
diabetes status were assessed. T-tests (two-tailed) for difference in means and Pearson chi-
square tests of independence for proportions and test for trend among demographic groupings 
were estimated.  
To examine whether there was a graded relationship between summed total pathogen 
burden and all-cause/CVD-related mortality, Kaplan-Meier survival curves were plotted for all-
cause and CVD-related mortality by pathogen burden level to first examine the unadjusted 
association between summed pathogen burden and mortality. Survival time was measured in 
months since mobile or home examination. Cox proportional hazard models were used to 
estimate the confounder adjusted HR and 95% CI for the association between pathogen burden 






(age, gender, race/ethnicity, country of origin and education level), then, in models additionally 
adjusted for clinical factors (BMI (kg/m
2
), smoking status and diabetes status.  
3.3 RESULTS 
Weighted estimates of the bivariate relationships between covariates of interest and 
summed total pathogen burden are shown in Table 3.1. The weighted proportion of individuals in 
each pathogen burden level ranging from 0 to 4 was 11.0%, 21.7%, 29.5%, 29.1% and 8.7%, 
respectively. Higher age, female gender, non-white race/ethnicity, country of origin outside the 
U.S., lower education level, low BMI (< 25 kg/m
2
) and high BMI (≥ 30 kg/m
2
) compared to 
medium BMI (25 ≤ BMI < 30) and reported diabetes were associated with increased pathogen 
burden. Although hypothesized as a potential confounder in the association between pathogen 
burden and mortality, smoking status was not associated with total pathogen burden in our study. 
There was a statistically significant trend for death from all-causes and CVD-related death with 
increasing pathogen burden. Overall mean survival duration since time of exam for those 
seropositive to zero pathogens was 16.1 years (193.5 ± 2.3 months), to one pathogen was 15.7 
years (188.1 ± 2.1 months), to two pathogens was 14.9 years (179.3 ± 2.0 months), to three 
pathogens was 14.4 years (172.7 ± 1.9 months) and to all four pathogens was 13.8 years  (165.2 
± 2.5).  During the mean 15.0 years of follow-up from exam, among subjects in our sample, the 
population estimate for the proportion dying from all causes was 21.0% and from CVD-related 
causes was 8.7%.  
 
 




Table 3.1. Demographic  and Clinical Characteristics (Weighted) by Summed Pathogen Burden Level Among Subjects Aged 25 
and Older in NHANES III 
Pathogen Burden Level 
N=6522 0 1 2 3 4 P-value 
Covariates (%)       
All-Cause Mortality       
Survived  13.2 24.0 29.2 26.4 7.2 <0.0001* 
Died  2.8 13.1 30.9 39.0 14.3  
Mean Survival Duration (months ± SE)  (193.5 ± 2.3) (188.1 ± 2.1) (179.3 ± 2.0) (172.7 ± 1.9) (165.2 ± 2.5) 0.0012
§
 
CVD-Related Mortality       
Survived  11.9 22.6 29.3 27.9 8.3 <0.0001* 
Died  1.9 12.4 31.7 40.9 13.1  
Age Category        
25-34 20.5 29.9 26.0 18.4 5.2 <0.0001 
35-44 11.5 24.7 31.1 25.3 7.3  
45-54 10.8 18.5 31.1 31.1 8.5  
55-64 4.4 18.6 32.0 34.6 10.5  
65-74 1.8 13.2 30.3 41.1 13.4  
75+ 1.0 6.2 28.2 47.8 16.8  
Gender       
Female 8.8 18.7 31.4 31.0 10.1 <0.0001* 
Male 13.7 24.9 27.5 26.9 7.2  
Race/Ethnicity       
Non-Hispanic White 13.3 25.0 31.1 25.4 5.2 <0.0001* 
Non-Hispanic Black 2.5 7.5 23.0 38.0 28.9  
Mexican-American 1.7 6.0 23.9 48.3 20.1  
Other 2.3 12.4 24.1 47.4 13.9  
Country of Origin
†
       
United States 12.3 23.5 30.1 26.5 7.6 <0.0001* 
Other 2.0 9.4 25.3 47.1 16.3  
Education Level
‡
       
< High School 3.6 9.0 26.3 44.6 16.5 <0.0001* 
High School 9.3 22.3 31.1 29.3 8.0  
> High School 17.4 29.4 30.3 18.7 4.2  




        
< 25 13.7 21.5 31.5 26.2 7.2 <0.0001* 
 




25 ≤ BMI < 30 9.3 23.1 27.9 30.1 9.5  
≥ 30 8.2 20.0 27.9 33.1 10.8  
Smoking Status       
Never 12.5 22.2 27.6 28.6 9.1 0.0639 
Former 10.3 22.0 30.8 29.8 7.1  
Current 9.6 20.7 31.0 29.0 9.7  
Diabetes§       
No 11.4 22.3 29.2 28.7 8.5 <0.0001* 
Yes 4.9 13.2 35.0 34.2 12.7  
*Significant at p<0.05, t-tests for difference in means and Pearson chi-square tests for differences in proportions or test for trend  
among demographic groupings were calculated. 
†
N=6516 due to 6 subjects missing data on country of origin. 
‡ 
N=6480 due to 42 subjects missing data on education level. 
±














 The Kaplan-Meier survival curves showing the unadjusted association between summed 
pathogen burden level and all-cause and CVD-related mortality are shown in Figures 3.1 and 3.2.  
 
Figure 3.1 Kaplan-Meier Survival Curve for All-Cause Mortality by Pathogen Burden Level. 
Unadjusted Kaplan-Meier survival curves for all-cause mortality by pathogen burden level for 
6522 subjects, ≥ 25 years of age, in the National Health and Nutrition Examination Survey 








Figure 3.2 Kaplan-Meier Survival Curve for Cardiovascular disease-related Mortality by 
Pathogen Burden Level. Unadjusted Kaplan-Meier survival curves for all-cause mortality by 
pathogen burden level for 6504 subjects, ≥ 25 years of age, in the National Health and Nutrition 










 Table 3.2 shows the HR and 95% CI from Cox proportional hazard models examining the 
association between summed total pathogen burden and all-cause/CVD-related mortality. After 
adjustment for age, gender, race/ethnicity, country of origin and education level, seropositivity for 
2, 3 or 4 pathogens were associated with all-cause mortality compared to seropositivity for 0 
pathogens, but did not follow a graded pattern.  After additional adjustment for BMI (kg/m
2
), 
diabetes status and smoking status, these associations were no longer statistically significant (HR 
(95% CI) of 1.31 (0.87, 1.95), 1.46 (0.98, 2.18), 1.30 (0.92, 1.84) and 1.46 (0.96, 2.22), 
respectively) and did not follow a graded pattern. Similarly, the in fully adjusted models, the 
association between each pathogen burden level and CVD-related mortality was not statistically 
significant, nor was there a graded relationship between increased pathogen burden and CVD-
related mortality. 
Table 3.2 Association Between Summed Pathogen Burden and All-Cause/Cardiovascular 
Disease-related Mortality Among Subjects Aged 25 and Older in NHANES III 
 Hazard Ratio and 95% Confidence Interval 












0 1.0 1.0 1.0 1.0 
1 1.37 (0.93, 2.00) 1.31 (0.87, 1.95) 1.58 (0.80, 3.15) 1.51 (0.72, 3.14) 
2 1.56 (1.06, 2.30)* 1.46 (0.98, 2.18) 1.80 (1.01, 3.21)* 1.73 (0.91, 3.29) 
3 1.45 (1.05, 2.01)* 1.30 (0.92, 1.84) 1.63 (0.89, 2.98) 1.48 (0.76, 2.88) 




Model 1 adjusted for age, gender, race/ethnicity, country of origin and 
education level (N=6474) for all-cause mortality and for CVD-related mortality (N=6456). 
ǂ
Model 2 additionally adjusted for BMI, diabetes status and smoking status for all-cause mortality 
(N=6441) and for CVD-related mortality (N= 6423). 
 
3.4 DISCUSSION 
To the best of our knowledge, our study is the first to utilize a large, nationally 
representative sample of U.S. adults aged 25 and older with up to 18.1 years of follow-up to 
examine whether there is a graded relationship between increasing pathogen burden with CMV, 
HSV-1 and -2 and H. pylori and all-cause as well as CVD-related mortality. The results of our 
study suggest that after confounder adjustment including age, gender, race/ethnicity, country of 
origin, education level, BMI (kg/m
2
), diabetes status and smoking status, there is not a graded 
relationship between increasing pathogen burden with CMV, HSV-1, HSV-2 and/or H. pylori and 
all-cause or CVD-related mortality in the U.S. adult population.  
Few studies have examined the relationship between total pathogen burden and all-
cause/CVD-related mortality and results across studies are conflicting.
60-62,119
 Most recently, a 
study by Elkind et al., measured the association between an infectious burden index (constructed 
by summing the beta coefficients for the effect of each pathogen for which individuals were 
seropositive on risk for stroke) and vascular, non-vascular and all-cause deaths among subjects 
40 years of age and older (mean age 68.4) from Manhattan, New York, without history of 
stroke.
119





(C. pneumoniae), CMV, HSV-1, HSV-2 and H. pylori), was associated with an increased risk for 
nonvascular deaths (HR per standard deviation change in IB 1.23, 95% CI 1.04, 1.45) in the fully 
adjusted model.
119
 However, after confounder adjustment, the index was no longer statistically 
significantly associated with risk for vascular deaths or deaths from all causes.
119
 In contrast, Zhu 
et al., examined the relationship between summed pathogen burden with CMV, Hepatitis A, HSV-
1 and 2 and all-cause death among a mostly male cohort of Utah residents, with a mean age of 
65.3 years and existing CAD. 
60
 The authors found a significant trend (p-value = 0.020) in risk for 
death from all-causes with increasing pathogen burden (although the risk for mortality associated 
with each pathogen burden level effects was not statistically significant).
60
 
Two other studies by Rupprecht et al. and Espinola-Klein et al., examined the association 
between summed pathogen burden with eight pathogens (HSV-1, HSV-2, CMV, Epstein-Barr 
virus, Haemophilus influenzae, C. pneumoniae  Mycoplasma pneumoniae and H. pylori) and 
CVD-related mortality among German subjects with existing coronary artery disease (CAD).
61,62
 
In both studies the authors found a significant trend in risk for CVD-related mortality with 
increasing pathogen burden of 4-5 and 6-8 pathogens compared to seropositivity for 0-3 
pathogens.
61,62
 Rupprecht et al. further examined the association between increased pathogen 
burden with bacterial and viral pathogens and CVD-related mortality, separately (comparing 
seropositivity for 2 vs. 0-1 pathogens and for 3-4 vs. 0-1 pathogens) finding that the association 
between increased pathogen burden with herpesviridae and CVD-related mortality was stronger 
than that with bacterial burden.
61
 However, the pathogen groupings were not mutually exclusive, 
so it is not possible to completely discern the effects of viral pathogen burden alone from co-




The study populations from these previous reports were older, mostly consisted of 
persons with existing CVD and who were from specific geographic regions (i.e. Utah, New York 
and Germany), thus their results may not be generalizable to the U.S. general population.
60-62,119
  
However, our study suggests, similar to Elkind et al., a lack of association between increased 
pathogen burden and all-cause/CVD-related mortality in persons without existing CVD.
119
 In 
contrast, the other previous studies suggest there is a significant association between increased 
pathogen burden and all-cause/CVD-related mortality among persons with existing CVD.
60-62
 
Because the study populations in several of the previous studies had existing CVD, it is possible 
that increased pathogen burden is particularly detrimental for CVD-related mortality among those 
with existing CVD. Espinola-Klein et al. for example, found that the effect of increased pathogen 
burden on CVD-related death was particular strong among those with advanced 
atherosclerosis.
62
 This may explain why our study, in a population-representative sample of the 
U.S., we did not identify a graded relationship between increased pathogen burden and all-





It is also possible that the particular combination of pathogens included in measures of 
summed pathogen burden in the studies by Rupprecht et al. and Espinola-Klein et al. are 
particularly detrimental for CVD-related mortality.
61,62
 For example, there is in vitro evidence 
suggesting that Chlamydia pneumoniae (C. pneumoniae), a persistent bacterial infection included 
in these previous studies, can stimulate the expression of CMV genes, thus these pathogens may 
biologically interact in such a way that co-infection with C. pneumoniae exacerbates the effect of 
CMV on atherosclerosis and mortality.
121
 Therefore, in our study, persons seropositive for CMV 
whom also had undetected seropositivity for C. pneumoniae may have elevated risk for mortality. 
Thus, if C. pneumoniae been included in our measure of summed pathogen burden, those 
individuals, whose risk for mortality was potentially higher due to co-infection with C. pneumoniae 
would have actually been categorized at a higher pathogen burden level. Overall, unmeasured 
co-infection with C. pneumoniae, as well as other persistent pathogens that have been implicated 
in chronic diseases, could have impacted our ability to detect a graded relationship between 
summed pathogen burden and mortality. Unfortunately, serologic results for only one of the 
bacterial pathogens examined in earlier studies, H. pylori, was available in NHANES III. Had we 
been able to include other persistent pathogens in our measure of summed pathogen burden it is 
possible that we would have detected a similar relationship between increased pathogen burden 
and all-cause/CVD-related mortality in our study, as was detected in previous studies. 
There are a few limitations to our study. We utilized the updated NHANES III Linked 
Mortality Public-use File which was subject to data perturbation in which synthetic data was 
substituted for the actual date of death and underlying cause of death for selected descendent 
records in order to reduce risk of respondent re-identification.
162
 Despite the data perturbation of 
date of death for selected decedents in the public-use file, a comparison study between the 
public-use and restricted-use file (which does not contain perturbed data) conducted by the 
NCHS, found that analysis of all-cause by sociodemographic factors including as age, sex, 
race/ethnicity and education level to be comparable across files and concluded that the 
discrepancies between the public-use and restricted-use file were minor and that analysts should 
use the public-use file with confidence.
162
 Importantly, mortality status was rigorously verified by 
two sources (National Death Index (NDI) and/or death certificate review).
140
 Furthermore, NDI is a 




Another limitation to our study is that we only had information on seropositivity and not 
immune response to infection. Because high antibody titer to persistent infections is likely a 
marker of “reactive” infection which may be associated both exacerbated damage to invaded host 
tissues and with increased levels of inflammation, it is likely that high antibody titer to an 
increased number of pathogens also plays an important role in determining risk for mortality.
178
 





pathogens for which and individual has a high antibody titer and mortality, two recent studies 
demonstrated that elevated CMV antibody titer was statistically significantly associated with 
mortality among elderly populations.
57,58
 Thus, it is possible that although we failed to detect a 
graded relationship between summed pathogen burden and all-cause/CVD-related mortality, we 
would have seen a trend for increasing risk for mortality with increasing number of pathogens for 
which individuals had a high antibody titer.  
3.5 Conclusion 
Overall, our findings indicate the absence of a graded relationship between increased 
summed pathogen burden with CMV, HSV-1, HSV-2 and/or H. pylori, and all-cause/CVD-related 
mortality in the general U.S. population aged 25 years and older. Taken together with evidence 
from other studies, it is possible that certain combinations of persistent pathogens may play a 
more important role in determining risk for mortality among persons with and without existing 
CVD. These results indicate that there is a need for future research that focuses not just on the 
relationship between the crude number of pathogens individuals are seropositive for, but which 
also explores other aspects of the relationship between total pathogen burden and risk for 
mortality such as the role of biological interactions between pathogens in determining risk for 
mortality. This study suggests that interventions focused solely on reducing the total number of 
persistent pathogens for which individuals are seropositive is unlikely to significantly impact 













Chapter 4  
Seropositivity for Specific Combinations of Persistent Pathogens and Risk for All-Cause and 
Cardiovascular Disease-related Mortality in the United States 
 
4.1 Background  
Over the past two decades there has been a growing interest in examining whether there 
is a monotonic relationship between seropositivity for an increased number of persistent 
pathogens and risk for chronic diseases and mortality.
44,60,62,179-181
  Persistent pathogens are 
linked to chronic disease via direct, pathogen-specific effects such as in the case of 
cardiovascular disease (CVD), in which certain pathogens invade vascular tissues and trigger 
atherogenesis.
45-49
 Initial infection as well as reactivation  with persistent pathogens triggers the 
release of acute phase proteins and increases levels of inflammatory markers linked to CVD and 
other chronic diseases.
50-56
 Thus, increased total pathogen burden is thought to increase risk for 
chronic disease and mortality due to an accumulation of pathogen-specific effects and increased 
levels of systemic inflammation.
94
  
Most studies utilize summed pathogen burden variables, defined as the total number of 
pathogens an individual tests seropositive for, based on antibody response, to examine whether 
there is a graded relationship between increased total pathogen burden and chronic 
disease/mortality. Three previous studies conducted among populations with existing CVD found 
a statistically significantly graded relationship between summed pathogen burden including 
variable pathogens across studies and all-cause/CVD-related mortality. These studies suggest 
that among persons with existing CVD, there is a monotonic relationship between total pathogen 
burden and mortality, regardless of pathogen type.  However, in our study described in chapter 3 
of this dissertation, we did not detect a graded relationship between summed pathogen burden 
with cytomegalovirus (CMV), herpes simplex virus-1 (HSV-1), herpes simplex virus-2 (HSV-2) 
and/or Helicobacter pylori (H. pylori) and all-cause/CVD-related mortality among a nationally 
representative population of persons 25 years of age and older. In contrast, we found that the risk 
for mortality associated with summed pathogen burden level 1 and 3 was similar, as was the risk 
for mortality associated with summed pathogen burden level 2 and 4 (see Table 3.2, Chapter 3). 
It is possible that discrepancies between our study and previous studies are due to population 
differences. However, it is also possible that other factors, such as the specific combinations of 





number of pathogens for which individuals are seropositive, in terms of determining risk for 
mortality in the general population. 
While summed pathogen burden variables may be useful for assessing whether there is 
a graded association between total pathogen burden and mortality, regardless of pathogen type, 
use of this variable limits the ability for researchers to identify whether seropositivity for specific 
combinations of pathogens, in addition to the crude number of pathogens individuals are 
seropositive for, plays an important role in determining risk for mortality. There are two main 
reasons why use of the summed pathogen burden variable may not have provided a complete 
assessment of risk for mortality related to persistent pathogens in our earlier study, warranting 
further exploration of the relationship between specific combinations of pathogens and risk for 
mortality among the general U.S. population. First, in models examining the association between 
summed pathogen burden and mortality, all persons seropositive to a given number of pathogens 
(i.e., classified as having the same summed pathogen burden level) are estimated as having the 
same risk for disease/mortality by the model, regardless of the specific combination of pathogens 
for which an individual is seropositive. For example, when two individuals are categorized as 
having a summed pathogen burden level of two, one of these individuals may be seropositive for 
HSV-1 and CMV and the other may be seropositive for H. pylori and Chlamydia pneumoniae (C. 
pneumoniae).  Thus, these two individuals would be categorized as having a summed pathogen 
burden level of two and therefore be estimated as having the same risk for mortality, despite 
being seropositive for two entirely different sets of pathogens. Second, assuming a monotonic 
relationship between summed pathogen burden level and risk for mortality whereby an increase 
in summed pathogen burden level leads to an increased risk for mortality implies that the risk for 
mortality associated with any specific combination of pathogens is greater than risk for mortality 
associated with all combinations of fewer pathogens, regardless of pathogen type.   
Although a graded relationship between total pathogen burden and mortality may exist in 
certain populations, there is also evidence that pathogens may biologically interact such that 
combined seropositivity could increase or decrease risk for mortality.
120,121,122
 The use of summed 
pathogen burden variables for examining the association between total pathogen burden and 
mortality, disregards potentially important variability in risk associated with different combinations 
of pathogens both within pathogen burden levels and across pathogen burden levels. Thus, while 
summed pathogen burden variables may be useful for examining the hypothesis that “more is 
worse” when it comes to total pathogen burden and risk for mortality, limiting the examination of 
the relationship between total pathogen burden and mortality to this variable, hinders an 
assessment of other factors that might play an important role in the association between total 
pathogen burden and mortality such as the specific combinations of pathogens for which 





To our knowledge, no study has explicitly examined the extent to which the specific 
combinations of pathogens for which individuals are seropositive predicts risk for mortality, 
beyond that of the use of summed pathogen burden variables in the general U.S. population. 
Therefore, the purpose of this study is to 1) estimate the combined effects of seropositivity to four 
persistent pathogens (CMV, HSV-1, HSV-2 and H. pylori) on all-cause/CVD-related mortality in a 
U.S. representative population of individuals ≥ 25 years of age and older, and 2) to compare the 
risk for mortality associated with seropositivity for each specific combination of pathogens among 
persons within the same pathogen burden level as well as among persons across different 
pathogen burden levels to assess the extent to which use of summed pathogen burden variables 
in models examining the association between total pathogen burden and mortality limit our ability 
to make inferences about the specific pathogens which alone, or in combination most increase 
risk for death.  
4.2 Methods  
Study population 
 Data come from the National Health and Nutrition Examination Survey (NHANES) III 
(1988–1994); a population-based, multistage stratified probability survey which collected 
information on the health and nutrition of the United States civilian non-institutionalized 
population. The survey was carried out by the National Center for Health Statistics (NCHS), 
Centers for Disease Control and Prevention. A total of 33994 subjects were interviewed in 
NHANES III, but our study sample is limited to subjects who were 25 years of age and older at 
time of examination (N=15242 (48.7%)), had mortality follow-up (N=15229 (99.9%)) and were 
tested for serostatus for all four pathogens (N=6522 (42.8%)). Sera was selected randomly for 
seropositivity testing, however, only subjects in phase I were tested for H. pylori, therefore, our 
analysis was limited to subjects tested for seropositivity for the other three pathogens in phase I. 
In addition, we used data from the NHANES III-Linked Mortality file in which the mortality status of 
NHANES III participants was determined by probabilistic matching between NHANES III 
participants and the U.S. National Death Index (NDI).
140
 Cause of death was unavailable for 18 
subjects, thus, these subjects were excluded from analysis for CVD-related mortality.  
Laboratory Analyses 
CMV-specific IgG was measured by a commercially available Enzyme Linked 
Immunosorbent Assay (ELISA) (Quest International, Inc., Miami, FL). Sera with values near the 
ELISA cutoff were confirmed with a second ELISA assay (bioMerieux, Inc., Durham, NC). If the 
results from the first two tests disagreed, an Immunofluorescence Assay (IFA) (Bion International, 
Inc., Park Ridge, IL), was used and results from this test were provided as the final seropositivity 
test result. The sensitivity and specificity of these tests have been estimated to be 98 and 99%, 
respectively.
67,141
 HSV-1 and HSV-2 seropositivity was assessed by solid-phase enzymatic 







 These immunodot assays have also been shown to have high sensitivity and 
specificity.
176
 Subjects 20 years and older from phase 1 (1988-1991) were tested for H. pylori 
antibody in 1996 using H. pylori IgG ELISA (Wampole Laboratories, Cranbury, NJ). The cut 
points for seropositivity to each infection are based on commercially available immunoassay 




Results from the IgG antibody tests for each pathogen were dichotomized as 
seronegative or seropositive based on the ELISA results. The summed pathogen burden level 
(i.e., the total number of pathogens for which subjects were seropositive) of subjects ranged from 
0- 4. A categorical variable was constructed in which subjects were classified according to the 
specific combination of pathogens for which they were seropositive (1 of 16 possible pathogen 
combinations). Specifically, subjects with a pathogen burden level of 0 were seronegative to all 
four pathogens (referent group), subjects with a pathogen burden level of 1 were seropositive to 
one of the four pathogens alone, subjects with a pathogen burden level of 2 were seropositive for 
one of six combinations of two pathogens (seropositivity to CMV and HSV-1 or CMV and HSV-2 
or CMV and H. pylori or HSV-1 and HSV-2 or HSV-1 and H. pylori or HSV-2 and H. pylori) , 
subjects with a pathogen burden level of 3 were seropositive for one of four pathogen 
combinations of three pathogens (seropositivity to CMV, HSV-1 and HSV-2, or CMV, HSV-1 and 
H. pylori, or CMV, HSV-2 and H. pylori, or HSV-1, HSV-2 and H. pylori) and subjects with a 
pathogen burden level of 4 were seropositive to all four pathogens.  
Mortality status was obtained by NCHS primarily from the National Death Index (NDI); 
however, other sources of mortality status included indication of deceased status from the Social 
Security Administration, the Centers for Medicare and Medicaid Services, or death certificate 
review.
140
 Cause of death was coded using the International Classification of Diseases, Ninth 
Revision (ICD-9) up until 1998 and ICD-10 for 1999-2006. All deaths before 1999 were recoded 
by the NCHS into comparable ICD-10 codes.
144
 ICD-10 codes I00-I99 were classified as CVD-
related deaths and included, causes of death such as hypertensive heart disease, atherosclerosis 
including coronary and cerebrovascular disease, heart failure, and aortic aneurysms. Persons 
who survived the entire follow-up period were administratively censored on December, 31
st
 2006. 
Follow-up time for each person was calculated in months as the difference between the NHANES 
III examination date and the last known date alive or censored.
144
 Persons who died of non-CVD 
causes were considered censored at the date of death for CVD mortality analysis. 
Weighted estimates of the bivariate relationships between covariates of interest and 
summed total pathogen burden were estimated in our previous study (see Table 3.1 in Chapter 
3). Covariates associated with summed pathogen burden level and hypothesized to be predictors 
of mortality including age, gender, race/ethnicity, country of origin, body mass index (BMI) 
(kg/m
2





years at examination was self-reported and treated as a continuous variable. Gender was 
dichotomized as female and male. Race/ethnicity was self-reported as non-Hispanic white, non-
Hispanic black, Mexican-American or Other. Country of origin was reported as the state or foreign 
country in which subjects were born and was categorized as U.S. or Other. Years of education 
was self-reported and treated as continuous. BMI (kg/m
2
) was computed from weight and 
standing height and categorized as BMI < 25, 25 ≤ BMI < 30 and BMI ≥ 30. Smoking status was 
self-reported and categorized into never (did not smoke 100+ cigarettes in one‟s lifetime), past 
(smoked 100+ cigarettes in one‟s lifetime but do not currently smoke) and current smoker 
(smoked 100+ cigarettes in one‟s lifetime and currently smoke). Diabetes was self-reported as 
whether a doctor ever informed subjects they had diabetes or not and dichotomized as reported 
or not reported.   
Statistical analyses 
Statistical analyses were performed using SAS, version 9.2, with SAS-callable SUDAAN, 
version 10.0.1 (SAS Institute, Inc., Cary, NC).
155
 All analyses used appropriate weights and 
adjustments for strata and clustering used in the complex study design in NHANES III. Bivariate 
relationships between summed pathogen burden and all-cause/CVD-mortality and survival 
duration as well as between summed pathogen burden and potential confounders including age, 
gender, race/ethnicity, country of origin, education level, BMI (kg/m
2
), smoking status and 
diabetes status were assessed previously (see Table 3.1, Chapter 3). We estimated the 
distribution of the specific combination of pathogens for which subjects were seropositive within 
each pathogen burden level, in order to better understand which specific combination of 
pathogens were most prevalent among persons within each pathogen burden level.   
To estimate the combined effects of seropositivity to four persistent pathogens (CMV, 
HSV-1, HSV-2 and H. pylori) on all-cause/CVD-related mortality we used Cox proportional hazard 
models to estimate the confounder adjusted HR and 95% CI for the association between each of 
the 15 pathogen burden combinations and all-cause/CVD-related mortality, compared to the 
referent category of seronegativity to all four pathogens. Models were adjusted for 
sociodemographic factors (age, gender, race/ethnicity, country of origin and education level), for 
clinical factors (BMI (kg/m
2
), smoking status and diabetes status. Next, we compared the HR for 
all-cause/CVD-related mortality yielded by each combination of pathogens within each pathogen 
burden level as well as across all pathogen burden levels to assess whether measuring pathogen 
specific estimates provides information above and beyond summed pathogen burden for all-
cause/CVD-related mortality outcomes. 
4.3 RESULTS 
Weighted estimates of the bivariate relationships between covariates of interest and 
summed total pathogen burden were estimated in our previous study (see Table 3.1, Chapter 3).  





white race/ethnicity, country of origin outside the U.S., lower education level, low BMI (< 25 
kg/m
2
) and high BMI (≥ 30 kg/m
2
) compared to medium BMI (25 ≤ BMI < 30) and reported 
diabetes were associated with increased pathogen burden. Although hypothesized as a potential 
confounder in the association between pathogen burden and mortality, smoking status was not 
associated with total pathogen burden in our study. There was a significant trend for death from 
all-causes and CVD-related death with increasing pathogen burden. Overall mean survival 
duration since time of exam for those seropositive to zero pathogens was 16.1 years (193.5 ± 2.3 
months), to one pathogen was 15.7 years (188.1 ± 2.1 months), to two pathogens was 14.9 years 
(179.3 ± 2.0 months), to three pathogens was 14.4 years (172.7 ± 1.9 months) and to all four 
pathogens was 13.8 years  (165.2 ± 2.5).  During the mean 15.0 years of follow-up from exam, 
among subjects in our sample, the population estimate for the proportion dying from all causes 
was 21.0% and from CVD-related causes was 8.7%.  
The weighted proportion of individuals within each pathogen burden level and the 
weighted proportion of individuals with each possible combination of pathogens are shown in 
Table 4.1 below.  
Table 4.1 Weighted Distribution of Seropositivity for Persistent Pathogens Across 
Pathogen Burden Level in Subjects Aged 25 and Older  in NHANES III 
 Pathogen Burden Level 
Pathogen Combinations (N=6522) 0 1 2 3 4 










HSV-1 --- 53.1% --- --- --- 
CMV --- 30.8% --- --- --- 
HSV-2 --- 10.5% --- --- --- 
H. pylori --- 5.6% --- --- --- 
CMV and HSV-1 --- --- 62.6% --- --- 
HSV-1 and H. pylori --- --- 12.3% --- --- 
HSV-1 and HSV-2 --- --- 10.0% --- --- 
CMV and HSV-2 --- --- 7.4% --- --- 
CMV and H. pylori --- --- 7.0% --- --- 
HSV-2 and H. pylori --- --- 0.7% --- --- 
CMV, HSV-1 and H. pylori --- --- --- 64.8% --- 
CMV, HSV-1 and HSV-2 --- --- --- 27.6% --- 
CMV, HSV-2 and H. pylori --- --- --- 3.8% --- 
HSV-1, HSV-2 and H. pylori --- --- --- 3.8% --- 
CMV, HSV-1, HSV-2 and H. pylori --- --- --- --- 100% 
 
The weighted proportion of individuals at each pathogen burden level were 11.0%, 
21.7%, 29.5%, 29.1% and 8.7%, for those with the pathogen burden level of 0, 1, 2, 3, and 4, 
respectively. Among those seropositive for one pathogen, the majority were seropositive to HSV-
1 or CMV (53.1% and 30.8%, respectively). Among those seropositive for two pathogens, the 
greatest proportion, were seropositive for CMV and HSV-1 combined (62.6%) and the lowest 
proportion of subjects were seropositive for HSV-2 and H. pylori (0.7%). Among those 





HSV-1 and H. pylori combined (64.8%) followed by CMV, HSV-1 and HSV-2 combined (27.6%) 
and 3.8% were seropositive for CMV, HSV-2 and H. pylori as well as for HSV-1, HSV-2 and H. 
pylori. 
Tables 4.2 and 4.3 show the HR (95% CI) from Cox proportional hazard models 
estimating the combined effect of seropositivity to each of the 15 pathogen burden combinations 
(compared to seropositivity to zero pathogens) on risk for all-cause/CVD-related mortality, 
respectively. After adjustment for age, gender, race/ethnicity, country of origin, education level, 
BMI (kg/m
2
), smoking status and diabetes status, the effect of each individual pathogen as well 
as the combined effect of all pathogen burden combinations were positively (although not all 
statistically significantly) associated with all-cause mortality/CVD-related except for the combined 
effect of seropositivity for HSV-1 and H. pylori on risk for CVD-related mortality. Overall, the 
combined effect of seropositivity to CMV and HSV-2 (HR 2.06, 95% CI 1.22, 3.47) as well as the 
combined effect of seropositivity for CMV, HSV-1 and HSV-2 (HR 1.52, 95% CI 1.01, 2.31) were 
statistically significantly associated with all-cause mortality, even after adjusting for age, gender, 
race/ethnicity, country of origin, education level, BMI (kg/m
2
), diabetes status and smoking status. 
For CVD-related mortality, combined seropositivity for CMV and HSV-2 (HR 4.05, 95% CI 2.07, 
7.91) and combined seropositivity for HSV-2 and H. pylori (HR 6.27, 95% CI 1.56-25.20) were 












Table 4.2 Combined Effect of Each Pathogen Combination on All-Cause Mortality By Pathogen Burden Level Among Subjects 
Aged 25 Years and Older in NHANES III 
 Pathogen Burden Level 
 0 1 2 3 4 
Pathogen Combinations Hazard Ratio and 95% Confidence Interval 
Seronegative for All Pathogens 1.00     
HSV-1 --- 1.08 (0.69, 1.70) --- --- --- 
HSV-2 --- 1.35 (0.73, 2.48) --- --- --- 
CMV --- 1.51 (0.93, 2.46) --- --- --- 
H. pylori --- 1.95 (0.89, 4.28) --- --- --- 
CMV and H. pylori --- --- 1.18 (0.66, 2.12) --- --- 
CMV and HSV-1 --- --- 1.40 (0.95, 2.06) --- --- 
HSV-1 and HSV-2 --- --- 1.43 (0.70, 2.91) --- --- 
HSV-1 and H. pylori --- --- 1.76 (0.96, 3.25) --- --- 
CMV and HSV-2 --- ---   2.06 (1.22, 3.47)* --- --- 
HSV-2 and H. pylori --- ---  2.22 (0.60, 8.15) --- --- 
CMV, HSV-1 and H. pylori --- --- --- 1.24 (0.88, 1.74)  --- 
HSV-1, HSV-2 and H. pylori --- --- --- 1.25 (0.50, 2.96)   --- 
CMV, HSV-2 and H. pylori --- --- --- 1.28 (0.62, 2.65)   --- 
CMV, HSV-1 and HSV-2 --- --- ---   1.52 (1.01, 2.31)*   --- 
CMV, HSV-1, HSV-2 and H. pylori --- --- --- --- 1.47 (0.96, 2.24) 
*Significant at p<0.05. Model adjusted for age, gender, race/ethnicity, country of origin, education level, body mass index kg/m
2
,  
diabetes status and smoking status (N=6456). CMV=cytomegalovirus, HSV-1=herpes simplex virus-1,  










































*Significant at p<0.05. Model adjusted for age, gender, race/ethnicity, country of origin, education level, body mass index kg/m
2
,  
diabetes status and smoking status (N=6423). CMV=cytomegalovirus, HSV-1=herpes simplex virus-1,  
HSV-2=herpes simplex virus-2 and H. pylori=Helicobacter pylori
Table 4.3 Combined Effect of Each Pathogen Combination on Cardiovascular Disease-Related Mortality By Pathogen Burden 
Level Among Subjects Aged 25 Years and Older in NHANES III 
 Pathogen Burden Level 
 0 1 2 3 4 
Pathogen Combinations Hazard Ratio and 95% Confidence Interval 
Seronegative to all pathogens 1.00     
HSV-1 --- 1.45 (0.64, 3.27) --- --- --- 
HSV-2 --- 2.56 (0.66, 9.94) --- --- --- 
CMV --- 1.36 (0.54, 3.41) --- --- --- 
H. pylori --- 2.27 (0.47, 10.90) --- --- --- 
CMV and H. pylori --- --- 1.24 (0.37, 4.17) --- --- 
CMV and HSV-1 --- --- 1.71 (0.87, 3.36) --- --- 
HSV-1 and HSV-2 --- --- 1.43 (0.70, 2.91) --- --- 
HSV-1 and H. pylori --- --- 1.65 (0.68, 3.98) --- --- 
CMV and HSV-2 --- ---   4.05 (2.07, 7.91)* --- --- 
HSV-2 and H. pylori --- --- 6.27 (1.56, 25.20)* --- --- 
CMV, HSV-1 and H. pylori --- --- --- 1.41 (0.70, 2.84) --- 
HSV-1, HSV-2 and H. pylori --- --- --- 0.53 (0.10, 2.84) --- 
CMV, HSV-2 and H. pylori --- --- --- 1.82 (0.73, 4.50) --- 
CMV, HSV-1 and HSV-2 --- --- --- 1.83 (0.94, 3.57) --- 






Next we compared the risk for mortality associated with each possible pathogen 
combination within the same pathogen burden level, finding that there was variability in the risk 
for all-cause/CVD-related mortality associated with each combination of pathogens within each 
pathogen burden level. For example, among those with a pathogen burden level of two, the HR 
(95% CI) for all-cause mortality for those seropositive for CMV and H. pylori was 1.18 (0.66, 2.12) 
whereas the HR (95% CI) for those seropositive for CMV and HSV-2 was 2.06 (1.22, 3.47), 
although differences were not statistically significant. For CVD-related mortality, among those 
seropositive for two pathogens, the HR (95% CI) for CVD-related mortality, among those with a 
pathogen burden level of 2, the HR (95% CI) for seropositivity for CMV and HSV-2 (4.05 (2.07, 
7.91)) was statistically significantly different from the HR (95% CI) for combined seropositivity for 
CMV and HSV-1 (1.71 (0.87, 3.36)) (Adjusted Wald F = 8.95, p-value = 0.0065) as well as from 
the HR (95% CI) for the combined effect for seropositivity for HSV-1 and HSV-2 (1.43 (0.70, 
2.91)) (Adjusted Wald F= 5.39, p-value=0.0294) and from the HR (95% CI) for combined 
seropositivity for HSV-1 and H. pylori (1.65 (0.68, 3.98)) (Adjusted Wald F= 4.88, p-value = 
0.0375). Thus, all pathogen burden combinations within the same pathogen burden level did not 
necessarily yield the same risk for all-cause/CVD-related mortality.  
Next, we compared the HRs and 95% CIs for all-cause/CVD-related mortality yielded by 
each combination of pathogens across all pathogen burden levels finding that the combined 
effect of seropositivity for all pathogen combinations on all-cause/CVD-related mortality was not, 
in all cases, greater than the risk for mortality associated with the combined effect of fewer 
pathogens.  For example, combined seropositivity for CMV and HSV-2 (HR 2.06, 95% CI 1.22, 
3.47), yielded a higher risk for all-cause mortality than combined seropositivity for all but one 
combination of three pathogens and a higher risk for all-cause mortality than for seropositivity for 
all four pathogens (p<0.05). Similarly, for CVD-related mortality, combined seropositivity for CMV 
and HSV-2 (HR 4.05, 95% CI 2.07, 7.91) and combined seropositivity for HSV-2 and H. pylori 
(HR 6.27, 95% CI 1.56, 25.20), yielded higher risks for mortality than nearly all combinations of 
seropositivity for three pathogens as well as combined seropositivity for all four pathogens 
(P<0.05). Thus, in our study, we found that the combined effect of the specific combinations of 
pathogens individuals could be seropositive for did not always yield a risk for all-cause/CVD-
related mortality that was greater than combinations of fewer pathogens at lower pathogen 
burden levels.  
4.4 DISCUSSION 
To the best of our knowledge, our study is the first to utilize a large, nationally 
representative sample of U.S. adults aged 25 and older with up to 18.1 years of follow-up (mean 
of 15.0 years) to estimate the combined effect of seropositivity for each combination of four 
persistent pathogens previously implicated in the etiology of several chronic diseases and all-





education level, BMI (kg/m
2
), diabetes and smoking status, the combined effect for seropositivity 
to CMV and HSV-2 (HR 2.06, 95% CI 1.22, 3.47)) as well as the combined seropositivity to CMV, 
HSV-1 and HSV-2 (HR 1.52, 95% CI 1.01, 2.31) were statistically significantly associated with all-
cause mortality and the combined effect for seropositivity for CMV and HSV-2 (HR 4.05, 95% CI 
2.07, 7.91) and the combined effect for seropositivity for HSV-2 and H. pylori (HR 6.27, 95% CI 
1.56-25.20) were statistically significantly associated with CVD-related mortality. 
We also examined the extent to which use of summed pathogen burden variables for 
modeling the relationship between total pathogen burden and mortality may limit the ability of 
researchers to identify the specific combinations of pathogens for which the combined effects are 
most detrimental to health. First, we assessed whether individuals within the same pathogen 
burden level have the same risk for mortality, regardless of pathogen combination. We found that 
the risk for all-cause/CVD-related mortality associated with combined effect of all specific 
combinations of pathogens individuals could be seropositive for within each pathogen burden 
level was not uniform. For example, for CVD-related mortality, among those seropositive for two 
pathogens, the HR (95% CI) among those with a pathogen burden level of 2, that were 
seropositive for CMV and HSV-2 was 4.05 (2.07, 7.91) whereas the HR (95% CI) for those 
seropositive for CMV and HSV-1 was 1.71 (0.87, 3.36) (Adjusted Wald F = 8.95, p-value = 
0.0065. In other words, all persons seropositive for two pathogens in our study did not have the 
same risk for mortality, regardless of pathogen type.  
Second, our study demonstrated that the risk for all-cause/CVD-related mortality for each 
pathogen burden combination within a given pathogen burden level, was not necessarily greater 
than that of all pathogen burden combinations at each lower pathogen burden level. For example, 
combined seropositivity for CMV and HSV-2, yielded a higher risk for all-cause and CVD-related 
mortality than combined seropositivity for all but one combination of three pathogens and a higher 
risk for all-cause mortality than for seropositivity for all four pathogens (p<0.05). Thus, in our 
study, we did not find that the risk for all-cause/CVD-related mortality for individuals with a given 
summed pathogen burden level was uniform, regardless of which combination of pathogens 
individuals were seropositive for, nor that increased summed pathogen burden level guaranteed 
an increased risk for all-cause/CVD-related mortality, regardless of pathogen combination. These 
results suggest that the use of summed pathogen burden variables to assess whether there is a 
monotonic relationship between total pathogen burden and mortality likely limits our ability to 
identify potentially significant variability in risk attributable to the specific combination of 
pathogens individuals are seropositive for. In addition, the risk associated with mortality for those 
categorized as having a particular pathogen burden level may be less a reflection of the total 
number of pathogens individuals are seropositive for than the result of particular combinations of 





To our knowledge no other studies have examined the association between the 
combined effect of specific combinations of pathogens and all-cause/CVD-related mortality. 
However, a recent study by Miggins et al., examined the association between non-specific viral 
and bacterial infection and mortality in a population based retrospective cohort study in which the 
infection and mortality status of immunocompetent but critically ill individuals admitted for hospital 
stay to the intensive care unit was obtained.
120
 The authors divided patients into four groups: 1) 
individuals without any documented infection at admission or during hospitalization, 2) individuals 
diagnosed with a viral infection during their hospitalization, 3) individuals diagnosed with a 
bacterial infection during their hospitalization and 4) individuals diagnosed with both viral and 
bacterial infections during their hospitalization (co-incident infection). Next, they compared the 
relative risk for those with co-incident infection to those with only viral or only bacterial infection, 
finding that those with bacterial infection alone, had a higher relative risk for death (RR 4.13, 95% 
CI 3.76, 4.53) than those with viral infection alone (RR 2.36, 95% 1.73, 3.24) and that there was 
significant additive interaction suggestive of biologic interaction between viral and bacterial 
pathogens in relation to risk for mortality.
120
 
Unlike our study, Miggins et al. did not examine the association between every specific 
combination of viral and/or bacterial infection individuals were seropositive for and mortality nor 
did they identify which particular viral or bacterial pathogens individuals were diagnosed with 
during hospitalization. However, the authors did estimate the risk for death for a few specific 
pathogens with and without concurrent bacterial infection, finding that the combined effect of 
diagnosis with CMV infection and bacterial infections was RR 6.66 (95% CI 4.35, 10.19) 
compared to an RR (95% CI) of 4.21 (2.07, 8.55) for those diagnosed with CMV infection but no 
bacterial infections (increased RR of 54%).
120
 Similarly, the RR (95% CI) for death for those 
diagnosed with HSV infection and bacterial infections was doubled compared to those diagnosed 
with HSV and no bacterial infection.
120
 The study by Miggins et al, similar to ours, implicates the 
herpeseviruses, CMV and HSV, in increasing risk for death, particularly among those co-infected 
with bacterial infections. Although this study was conducted among a very specific cohort of 
critically ill patients, it adds evidence supporting the hypothesis that pathogens likely biologically 




Identifying which persistent pathogens, individually, or in combination, are most strongly 
associated with mortality and identifying how pathogens interact to increase risk for chronic 
disease and death remains important for focusing interventions that reduce exposure to and/or 
transmission of infections most detrimental to health. Our findings as well as those by Miggins et 
al., suggest that herpesviruses may play an important role in determining risk for all-cause/CVD-
related mortality. Furthermore, Miggins et al., demonstrated that the effect of herpesviruses on 
risk for death was augmented by bacterial co-infection.
120





seropositive for HSV-2 as well as the bacterial infection H. pylori had a statistically significantly 
increased risk for CVD-related mortality and that there was evidence of biological interaction 
between the two pathogens (relative risk due to biologic interaction > 0, data not shown). 
156
 
However, we were unable to include other persistent pathogens that have been associated with 
chronic disease and/or mortality in previous studies such as C. pneumonaie
101, 156,182-184
 because 
they were not serologically tested for in NHANES III. Therefore, other bacterial pathogens that 
may also play an important role in determining risk for mortality and/or interact with pathogens 
included in this study in such a way that their inclusion would have altered the risk for all-
cause/CVD-related mortality associated with certain combinations of pathogens. Therefore, we 
cannot rule out that the associations between specific combinations of pathogens and all-
cause/CVD-related mortality observed in our study are not due to unmeasured co-infection with 
other persistent pathogens. Further research examining the risk for mortality associated with a 
comprehensive variety of pathogen combinations is needed to fully understand which particular 
combinations of pathogens are most strongly associated with death in the U.S. general 
population. 
To our knowledge, only one other recent study by Elkind et al., measured the association 
between pathogen burden and vascular, non-vascular and all-cause deaths utilizing a measure of 
pathogen burden other than summed pathogen burden level.
119
 Specifically, Elkind et al. 
constructed an infectious burden index, by summing the beta coefficients for the effect of each 
pathogen on risk for stroke for which a subject was seropositive (including Chlamydia 
pneumoniae (C. pneumoniae), CMV, HSV-1, HSV-2 and H. pylori).
119
 They found that the 
infectious burden index was associated with an increased risk for non-vascular deaths (HR per 
standard deviation change in IB 1.23, 95% CI 1.04, 1.45) in the fully adjusted model. However, 
after confounder adjustment, the infectious burden index was no longer statistically significantly 
associated with risk for vascular deaths or deaths from all causes among a cohort of subjects 40 
years of age and older from Manhattan, New York, without history of stroke.
119
 
In constructing an infectious burden index, which summed the beta coefficients for the 
association between each pathogen and risk for stroke that an individual was seropositive for, 
Elkind et al., utilized a measure of total pathogen burden which attempted to overcome the 
methodologic limitations associated with using summed pathogen burden measures to model the 
association between total pathogen burden and mortality.
119
 Namely, the index modeled the 
association between total pathogen burden and mortality, allowing for the risk for death 
associated with different combinations of pathogens to vary according to the specific combination 
of pathogens individuals are seropositive for.
119
 However, the weighting approach applied to this 
measure of total pathogen burden assumes the combined effect of seropositivity to multiple 
pathogens is strictly additive, i.e., there is not biologic interaction between pathogens which could 





the sum of the effect of the individual pathogens. Although it was not part of our main analysis, 
we did observe evidence of both positive and negative interaction on the additive scale 
(suggestive of biologic interaction) for certain combinations of pathogens in determining risk for 
mortality in our study.  Taken together with the study by Miggins et al., the assumption that the 
effect of pathogens on risk for mortality is strictly additive may be problematic.
120
  For these 
reasons, studies that have utilized summed pathogen burden variables or other infectious burden 
indexes in modeling the association between total pathogen burden and mortality do so at the 
expense of identifying which persistent pathogens alone or in combination are most detrimental to 
health.   
There are a few limitations to our study. We utilized the updated NHANES III Linked 
Mortality Public-use File which was subject to data perturbation in which synthetic data was 
substituted for the actual date of death and underlying cause of death for selected descendent 
records in order to reduce risk of respondent re-identification.
162
 Despite the data perturbation of 
date of death for selected decedents in the public-use file, a comparison study between the 
public-use and restricted-use file (which does not contain perturbed data) conducted by the 
NCHS, found that analysis of all-cause by sociodemographic factors including as age, sex, 
race/ethnicity and education level to be comparable across files and concluded that the 
discrepancies between the public-use and restricted-use file were minor and that analysts should 
use the public-use file with confidence.
162
 Importantly, mortality status was rigorously verified by 
two sources (National Death Index (NDI) and/or death certificate review).
140
 Furthermore, NDI is a 




In conclusion, the potential for specific combinations of pathogens to strongly influence 
risk for mortality, calls into question the use of summed pathogen variables alone in studies 
examining the association between total pathogen burden and mortality. Our results suggest that 
due to potentially important variability in risk for mortality associated with specific combinations of 
pathogens within and across pathogen burden level,  researchers should also consider the types 
of pathogens that individuals are exposed to at each pathogen burden level in order to identify 
which particular pathogens seropositivity most increases risk for mortality. While measures of 
summed pathogen burden may be useful for examining the hypothesis that “more is worse” when 
it comes to the relationship between total pathogen burden and mortality, use of this variable is 
done so at the expense of identifying which persistent pathogens alone or in combination are 
most detrimental to health. We found that seropositivity for specific combinations of pathogens 
(herpesviruses in particular) may play an important role in determining risk for all-cause/CVD-
related mortality in the general U.S. population. Thus, interventions focused solely on reducing 





mortality in the U.S., whereas interventions that focus on the elimination of specific combinations 
of pathogens such as CMV and HSV-2 may provide a better target for reducing the burden of 
mortality among infected populations. If herpesviruses such as CMV, HSV-1 and HSV-2 as well 
as the bacterial pathogen, H. pylori, are potentially driving the association between pathogen 
burden and risk for mortality in studies of summed pathogen burden, emphasis should be made 
on determining the specific mechanisms by which these particular pathogens act together to 
increase risk for death and whether delayed acquisition and/or improved immune control of these 





Chapter 5  
Conclusion 
5.1 Conclusion 
 This dissertation examined the association between persistent pathogens, inflammation 
and risk for all-cause/cardiovascular disease (CVD)-related mortality in the general U.S. 
population 25 years of age and older. This work demonstrated that seropositivity for CMV is 
associated with all-cause mortality but was not statistically significantly associated with CVD-
related mortality. However, the combined effect of cytomegalovirus (CMV) seropositivity and high 
C-reactive protein (CRP) level was associated with a greater risk for all-cause/CVD-related 
mortality than either CMV seropositivity or high CRP level alone suggesting that both CMV 
infection and CRP levels should be considered interventions focused on reducing mortality in the 
United States general population. In addition, we did not detect a graded relationship between 
summed pathogen burden with CMV, herpes simplex virus-1 (HSV-1), herpes simplex virus-2 
(HSV-2) and/or Helicobacter pylori (H. pylori) and all-cause/CVD-related mortality. Last, we 
estimated the risk for mortality associated with the combined effect of seropositivty for each 
combination of seropositivity with CMV, HSV-1, HSV-2 and/or H. pylori and assessed the extent 
to which use of summed pathogen burden variables for modeling the association between total 
pathogen burden and mortality limits the ability of researchers to identify the specific 
combinations of pathogens most strongly associated with risk for mortality. We found that the risk 
for all-cause/CVD-related mortality was not uniform within pathogen burden levels as is assumed 
in models using measures of summed pathogen burden. Furthermore, the risk for mortality 
associated with specific combinations of pathogens was not in all cases greater than that yielded 
by seropositivity for fewer pathogens. Thus, increased pathogen burden did not increase risk for 
all-cause/CVD-related mortality, regardless of pathogen type as hypothesized in models using 
measures of summed pathogen burden to examine whether there is a graded relationship 
between total pathogen burden and mortality. Importantly, we identified particular combinations of 
pathogens that were statistically significantly associated with increased risk for all-cause mortality 
(combined seropositivity for CMV and HSV-2 and combined seropositivity for CMV, HSV-1 and 
HSV-2) and with CVD-related mortality (combined seropositivity for CMV and HSV-2 and 
combined seropositivity for HSV-2 and H. pylori).  
 These findings provide a major contribution to the current understanding of the 
relationship between persistent pathogens, inflammation and risk for all-cause/CVD-related 





especially in conjunction with elevated CRP level in predicting all-cause and CVD-related 
mortality and supports interventions aimed at the elimination of CMV infection via the 
development and administration of treatments or vaccines and/or targeting the interaction of 
infection and CRP levels for reducing mortality rates in the United States adult population.  
 Further, this work indicates that research examining the association between total pathogen 
burden and mortality should shift away from measures of summed pathogen burden and instead 
focus on examining the role of seropositivity for specific combinations of pathogens in 
determining risk for mortality in order to focus interventions on the elimination of pathogens that 
are most detrimental to health in the general U.S. population. 
5.2 Aim 1  
The first aim of this dissertation examined whether seropositivity for CMV predicted all-
cause as well as CVD-related mortality in the U.S. general population and whether CRP mediated 
or modified the association in a U.S representative population 25 years of age and older. CMV 
seropositivity was statistically significantly associated with all-cause mortality (HR 1.19, 95% CI 
1.01, 1.40), but not CVD-related mortality (HR 1.19, 95% CI 0.95, 1.49) in models adjusted for 
age, gender, race/ethnicity, country of origin, education level, body mass index, diabetes status 
and smoking status. Further adjustment for CRP level did not attenuate this relationship. When 
we examined the combined effect of CMV seropositivity and high CRP level, we found the 
combined effect of these factors to be statistically significantly associated with both all-cause and 
CVD-related mortality and to be greater than risk for mortality associated with either factor alone. 
 Aim 1 fills several gaps in the current literature examining the relationship between CMV, 
inflammation and mortality. First, it establishes a significant relationship between CMV 
seropositivity and all-cause mortality in the general U.S. population. This relationship has been 
described earlier in studies conducted among specialized populations of older age individuals and 
specific race/ethnic or gender groups. CMV seropositivity was not statistically significantly 
associated with CVD-related mortality, however, it is possible that the strong relationship between 
CMV and all-cause mortality observed in this study indicates that CMV seropositive subjects are 
dying of competing causes before they have the chance to develop CVD, attenuating the 
relationship between CMV and CVD-related mortality. We did find that the combined effect of 
CMV seropositivity and high CRP level was significantly associated with both all-cause and CVD-
related mortality and the combined effect of these factors was greater than the effect of CMV 
seropositivity alone or high CRP level alone. These findings lend support for interventions that 
focus on both preventing CMV infection and decreasing CRP levels for decreasing risk for 
mortality in the general U.S. population.  
 CMV has been previously linked to a variety of chronic diseases including CVD, physical 
and cognitive impairment and cancer and this study establishes that CMV seropositivity is also 
associated with all-cause mortality in the general U.S. population.
38, 39, 57, 72-75





impact risk for chronic disease in part via direct effects such as the ability to invade vascular 
tissues and cause vascular damage or the ability to impact the regulation of cellular process such 
as cell migration and apoptosis which influence the development of cell proliferation and 
cancer.
51,94
 In addition, CMV is thought to impact risk for chronic diseases of inflammation-related 
etiology because this infection is subject to “reactivation” during times of stress, 
immunosupression and ageing and viral replication may lead to the release of acute phase 
proteins and inflammatory markers.
50,80,87-90
 Furthermore, the pathogen-specific effects of 
persistent infections that are “reactive” are likely to be exacerbated.
79-86
 It is possible that, 
elevated CRP could be marker of “reactivating” CMV infection, whereas low CRP level may 
indicate resolved or “latent” CMV infection. However, elevated CRP levels may also represent 
acute infection or injury not necessarily related to CMV infection and thus, CRP levels may be 
elevated in persons seropositive for CMV for other reasons. Because elevated CRP levels have 
been implicated in CVD and mortality independent of CMV infection, CMV infection and elevated 
CRP levels may in some cases, compete to increase risk for mortality whereas in other cases, 
CMV infection in conjunction with elevated CRP may be indicative of “reactive” CMV infection 
which is associated with exacerbated effects on mortality. 
Overall, if CMV infection plays a strong role in the etiology of all-cause and CVD-related 
mortality in conjunction with high CRP level, the elimination of CMV infection via the development 
and administration of treatments or vaccines and/or targeting the interaction of infection and CRP 
levels may reduce mortality rates in the United States. Furthermore, if subclinical “reactive” CMV 
infection is most important in the etiology of mortality, then situations that cause CMV reactivation 
over the lifecourse, such as stress, inflammation caused by co-infections, immunosuppression 
and aging may play important key roles in determining the extent to which CMV infection is 
detrimental to health. Since seropositivity as well as immune response for CMV patterns strongly 
by SEP, interventions that focus on the prevention of primary CMV infection as well as CMV 
“reactivation” could also serve as a novel point of intervention for reducing social disparities in 
mortality observed in the United States.  
5.3 Aim 2  
The second aim of this dissertation examined whether there is a graded relationship 
between increasing pathogen burden with CMV, HSV-1 and -2 and H. pylori and all-cause as well 
as CVD-related mortality.  In addition, the second aim assessed the combined effect of pathogen 
burden and CRP on all-cause/CVD-related mortality in a U.S representative population 25 years 
of age and older. There was not a graded relationship between summed pathogen burden with 
these four pathogens and risk for all-cause/CVD-related mortality in models adjusted for age, 
gender, race/ethnicity, country of origin, education level, body mass index, diabetes status and 





Aim 2 fills several gaps in the current literature on summed pathogen burden, 
inflammation and mortality. First, previous studies examining the relationship between summed 
pathogen burden and all-cause or CVD-related mortality, were conducted among older study 
populations from specific geographic regions and primarily among persons with existing CVD. 
Thus, this work highlights for the first time the relationship between summed pathogen burden 
and mortality in the general U.S. population and shows that there is no significant graded 
relationship between summed pathogen burden with these particular pathogens and mortality. 
It has been hypothesized that “more is worse” in terms of the number of pathogens to which 
individuals are seropositive in predicting risk for mortality and that increased pathogen burden 
impacts risk for mortality in part through increasing systemic inflammation. However, the results 
of our study suggest that other factors, such as the specific combinations of pathogens 
individuals are seropositive for, may also be important for determining risk for mortality in the US 
general population.  
Given that seropositivity for specific combinations of persistent pathogens may impact 
risk for all-cause and CVD-related mortality differently in populations with and without existing 
CVD, future research examining the role of specific combinations of pathogens and inflammation 
in determining risk for all-cause/CVD-related mortality is warranted. Identifying the specific 
pathogens that alone, or in the presence of co-infection are most detrimental to mortality would 
inform future interventions and/or treatments focused on infection-related prevention of mortality. 
Therefore, this dissertation assesses whether specific combinations of pathogens influences 
mortality in the US population in Aim 3. 
5.4 Aim 3 
The third aim of this dissertation estimated the combined effect for each combination of 
four persistent pathogens (CMV, HSV-1, HSV-2 and/or H. pylori) previously implicated in the 
etiology of several chronic diseases, and all-cause/CVD-related mortality in a U.S representative 
population 25 years of age and older. We found that after adjustment for age, gender, 
race/ethnicity, country of origin, education level, BMI (kg/m
2
), diabetes and smoking status, 
combined seropositivity for CMV and HSV-2 (HR 2.06, 95% CI 1.22, 3.47)) and combined 
seropositivity for CMV, HSV-1 and HSV-2 (HR 1.52, 95% CI 1.01, 2.31) were statistically 
significantly associated with all-cause mortality and combined seropositivity for CMV and HSV-2 
(HR 4.05, 95% CI 2.07, 7.91) and combined seropositivity for HSV-2 and H. pylori (HR 6.27, 95% 
CI 1.56-25.20) were statistically significantly associated with CVD-related mortality. 
We also examined the extent to which use of summed pathogen burden variables for 
modeling the relationship between total pathogen burden and mortality may limit the ability of 
researchers to identify the specific combinations of pathogens for which the combined effects are 
most detrimental to health. We found that the risk for all-cause/CVD-related mortality for 





combination of pathogens individuals were seropositive for, nor that increased summed pathogen 
burden level guaranteed an increased risk for all-cause/CVD-related mortality, regardless of 
pathogen combination. These results suggest that the use of summed pathogen burden variables 
to assess whether there is a monotonic relationship between total pathogen burden and mortality 
likely limits our ability to identify potentially significant variability in risk attributable to the specific 
combination of pathogens individuals are seropositive for. In addition, the risk associated with 
mortality for those categorized as having a particular pathogen burden level may be less a 
reflection of the total number of pathogens individuals are seropositive for than the result of 
particular combinations of pathogens that in combination, strongly increase or decrease risk for 
mortality.  
In our case, our earlier study in chapter 3 (Aim 2) did not find an association between 
summed pathogen burden and mortally.  Other studies have identified such a relationship but 
primarily among older study populations, from specific geographic regions and with existing CVD.  
It is possible that regardless of the results whether null or significant for the association between 
summed pathogen burden and mortality, these earlier studies are not capturing important 
variability attributed to the types and combinations of pathogens that may contribute to mortality 
risk.  Aim 3, therefore, fills several gaps in the current literature examining the relationship 
between total pathogen burden and mortality. First, the majority of previous studies examining the 
relationship between total pathogen burden and mortality have utilized summed pathogen burden 
variables for modeling the association and to our knowledge no previous studies have estimated 
the risk for mortality for the combined effect of specific combinations of persistent pathogens. This 
study is also the first to assess the extent to which the use of summed pathogen burden variables 
limits the ability of researchers to identify which particular pathogens alone, or in combination are 
most detrimental to health. Importantly, this study identifies several combinations of pathogens 
that are associated with increased risk for all-cause and CVD-related mortality among the general 
U.S. population aged 25 and older.  
Identifying which persistent pathogens, individually, or in combination, are most strongly 
associated with mortality and identifying how pathogens interact to increase risk for chronic 
disease and death remains important for focusing interventions that reduce exposure to and/or 
transmission of infections most detrimental to health. Our findings suggest that herpesviruses 
may play an important role in determining risk for all-cause/CVD-related mortality.  Interventions 
focused solely on reducing the number of pathogens individuals are seropositive for may not 
eliminate the pathogens most detrimental for mortality In contrast, interventions that focus instead 
on the elimination of specific combinations of pathogens that are most strongly associated with 
increased mortality in specific at-risk populations are more likely to be effective at reducing 
infection-related mortality. If herpesviruses such as CMV, HSV-1 and HSV-2 as well as the 





and risk for mortality, emphasis should be made on determining the specific mechanisms by 
which these particular pathogens act together to increase risk for death and whether delayed 
acquisition and/or improved immune control of these infections over the life course could serve to 
decrease risk for mortality. 
These findings indicate that future research should examine both the role of summed 
pathogen burden as well as the role of specific combinations of pathogens in determining risk for 
mortality in order to better understand how pathogen burden acts to increase risk for mortality. 
Although measures of summed pathogen burden are useful for examining whether there is a 
graded relationship between total pathogen burden and risk for mortality, regardless of pathogen 
type, limiting the examination of the relationship between total pathogen burden and mortality to 
testing the “more is worse” hypothesis limits the ability of researchers to identify which persistent 
pathogens alone or in combination are most detrimental to health.    
5.5 Dissertation summary  
Using population-based data on persons 25 years of age and older from NHANES III, this 
dissertation demonstrated that seropositivity for CMV increased risk for all-cause mortality, 
independent of CRP level, but not CVD-related mortality. However, the combined effect of these 
factors on risk for all-cause/CVD-related mortality was greater than risk for both all-cause/CVD-
related mortality associated with either factor alone. These findings support the hypothesis that 
CMV infection, especially in conjunction with elevated inflammation, which may be a marker of 
“reactive” infection may play an important role in predicting risk for mortality and supports future 
interventions that focus on the elimination of CMV infection via the development and 
administration of treatments or vaccines and/or targeting the interaction of infection and CRP 
levels may reduce mortality rates in the United States. 
In addition, we found that there was not a graded relationship between summed 
pathogen burden with CMV, HSV-1, HSV-2 and/or H. pylori and all-cause/CVD-related mortality 
and the combined effect of pathogen burden level and CRP level on mortality also did not follow a 
graded pattern. These findings indicate that other factors, such as the specific combinations of 
pathogens individuals are seropositive for, may play a more important role in determining risk for 
mortality in the general U.S. population.  Last, we examined the association between 
seropositivity for specific combinations of pathogens and risk for all-cause/CVD-related mortality 
finding the risk for all-cause/CVD-related death was not uniform within pathogen burden levels 
and risk for mortality associated with specific combinations of pathogens was not in all cases 
greater than that yielded by seropositivity for fewer pathogens. In addition, particular 
combinations of pathogens were statistically significantly associated with increased risk for all-
cause mortality (seropositivity for CMV and HSV-2 and seropositivity for CMV, HSV-1 and HSV-2) 
and with CVD-related mortality (seropositivity for CMV and HSV-2 and seropositivity for HSV-2 





of pathogens individuals are seropositive for are unlikely to eliminate the pathogens most 
detrimental for mortality in specific populations in the U.S and that interventions should focus 
instead on the elimination of specific combinations of pathogens most detrimental to health to 
have the greatest impact on decreasing mortality in the U.S.  
Taken together, this dissertation benefits the public health by clarifying the role of CMV, a 
persistent pathogen implicated in the etiology of numerous chronic diseases, inflammation in 
determining risk for all-cause/CVD-related mortality. Furthermore, this work betters our 
understanding of the association between summed pathogen burden level and risk for all-
cause/CVD-related mortality compared to that of seropositivty for specific combinations of 
pathogens for determining risk for mortality. These results have important implications for future 
public health efforts designed to reduce mortality via infection and inflammation-related pathways.   
5.6 Strengths and limitations  
This dissertation is the first to examine the relationship between persistent pathogens, 
inflammation and all-cause as well as CVD-related mortality in a U.S. nationally representative 
population of individuals 25 years of age and older allowing generalizability of our results to the 
general U.S. population. Furthermore, this was the first study to explicitly examine the extent to 
which the use of summed pathogen burden variables for modeling the relationship between total 
pathogen burden and mortality limit the ability of researchers to identify the specific combinations 
of pathogens that most increase risk for mortality. In addition, measures of pathogen serostatus 
and CRP level were laboratory confirmed and measures by standard methodologies. We were 
also able to control for several covariates of interest including age, gender, race/ethnicity, body 
mass index, diabetes status, smoking status and NSAID use in our statistical analysis. Last, 
mortality status was rigorously verified by the National Death Index (NDI), a validate method for 
matching deaths in the U.S. to population-based datasets and for obtaining cause of death, as 
well as by  death certificate review. 
Several limitations are also noteworthy. First, we utilized the updated NHANES III Linked 
Mortality Public-use File which was subject to data perturbation in which synthetic data was 
substituted for the actual date of death and underlying cause of death for selected descendent 
records in order to reduce risk of respondent re-identification. However, a comparison study 
between the public-use and restricted-use file (which does not contain perturbed data) conducted 
by the National Center for Health Statistics, found that analysis of all-cause and cause-specific 
mortality by various sociodemographic were comparable across files.  
Another limitation to our study is that we only had information on seropositivity for 
persistent pathogens and not immune response to infection and data for only one marker of 
systemic inflammation, CRP. Because high antibody titer to persistent infections is likely a marker 
of “reactive” infection which may be associated both exacerbated damage to invaded host tissues 





plays an important role in determining risk for mortality. In addition, approximately 64% of our 
study population had CRP levels under the limit of detection (< 0.3 mg/dl), because more 
sensitive assays that are currently available for measurement of high-sensitivity CRP below this 
limit of detection were not used in NHANES III, making it difficult to examine CRP levels 
continuously. Therefore, another limitation of our study is that were unable to examine the 
relationship between pathogen antibody titer and CRP level more closely, which might have 
allowed us to identify a more precise interaction between CMV and CRP levels and their effect on 
all-cause and CVD-related mortality. Last, other inflammatory markers that have been shown to 
be association with individual pathogens as well as increased pathogen burden and might also 
have a significant role in the pathway between and mortality, such as IL-6, are not available in 
NHANES III. Thus, it was not possible to determine whether other inflammatory markers in 
addition to CRP, play a role in the relationship between persistent pathogens and mortality.  
Last, we were unable to include other persistent pathogens that have been associated 
with chronic disease and/or mortality in previous studies because they were not serologically 
tested for in NHANES III. Therefore, other viral or bacterial pathogens that may also play an 
important role in determining risk for mortality and/or interact with pathogens included in this 
study in such a way that their inclusion would have altered the risk for all-cause/CVD-related 
mortality associated with certain combinations of pathogens. Therefore, we cannot rule out that 
the lack of graded relationship between summed pathogen burden and all-cause/CVD-related 
mortality observed in our study nor the associations between specific combinations of pathogens 
and all-cause/CVD-related mortality observed in our study are not due to unmeasured co-
infection with other persistent pathogens. Further research examining the risk for mortality 
associated with a comprehensive variety of pathogen combinations is needed to fully understand 















(1) Sorlie PD, Backlund E, Keller JB. US mortality by economic, demographic, and social 
characteristics: the National Longitudinal Mortality Study. Am J Public Health 1995; 85: 949-56. 
(2) Manton KG, Stallard E, Corder L. Education-specific estimates of life expectancy and age-
specific disability in the U.S. elderly population: 1982 to 1991. J Aging Health 1997; 9: 419-50. 
(3) Fried LP, Kronmal RA, Newman AB, et al. Risk factors for 5-year mortality in older adults: the 
Cardiovascular Health Study. JAMA 1998; 279: 585-92. 
(4) Crimmins EM, Saito Y. Trends in healthy life expectancy in the United States, 1970-1990: 
gender, racial, and educational differences. Soc Sci Med 2001; 52: 1629-41. 
(5) Singh GK, Siahpush M. Widening socioeconomic inequalities in US life expectancy, 1980-
2000. Int J Epidemiol 2006; 35: 969-79. 
(6) Muntaner C, Hadden WC, Kravets N. Social class, race/ethnicity and all-cause mortality in the 
US: longitudinal results from the 1986-1994 National Health Interview Survey. Eur J Epidemiol 
2004; 19: 777-84. 
(7) Lin CC, Rogot E, Johnson NJ, Sorlie PD, Arias E. A further study of life expectancy by 
socioeconomic factors in the National Longitudinal Mortality Study. Ethn Dis 2003; 13: 240-7. 
(8) Rogot E, Sorlie PD, Johnson NJ. Life expectancy by employment status, income, and 
education in the National Longitudinal Mortality Study. Public Health Rep 1992; 107: 457-61. 
(9) Kitagawa EM, Hauser PM. Differential Mortality in the United States: A Study 
in Socioeconomic Epidemiology. Cambridge, MA.: Harvard University Press; 1973. 
(10) Lynch J, Smith GD, Harper S, Hillemeier M. Is income inequality a determinant of population 
health? Part 2. U.S. National and regional trends in income inequality and age- and cause-
specific mortality. Milbank Q 2004; 82: 355-400. 
(11) Crimmins EM, Kim JK, Seeman TE. Poverty and biological risk: the earlier "aging" of the 
poor. J Gerontol A Biol Sci Med Sci 2009; 64: 286-92. 
(12) Jemal A, Ward E, Anderson RN, Murray T, Thun MJ. Widening of socioeconomic inequalities 
in U.S. death rates, 1993-2001. PLoS One 2008; 3: e2181. 
(13) Hadden WC, Rockswold PD. Increasing differential mortality by educational attainment in 
adults in the United States. Int J Health Serv 2008; 38: 47-61. 
(14) Meara ER, Richards S, Cutler DM. The gap gets bigger: changes in mortality and life 
expectancy, by education, 1981-2000. Health Aff (Millwood) 2008; 27: 350-60. 
(15) Cristia JP. Rising mortality and life expectancy differentials by lifetime earnings in the United 
States. J Health Econ 2009;. 
(16) Adler NE, Newman K. Socioeconomic disparities in health: pathways and policies. Health Aff 





(17) Adler NE, Ostrove JM. Socioeconomic status and health: what we know and what we don't. 
Ann N Y Acad Sci 1999; 896: 3-15. 
(18) Baum A, Garofalo JP, Yali AM. Socioeconomic status and chronic stress. Does stress 
account for SES effects on health? Ann N Y Acad Sci 1999; 896: 131-44. 
(19) Anderson NB, Armstead CA. Toward understanding the association of socioeconomic status 
and health: A new challenge for the biopsychosocial approach. Psychosomatic Medicine 1995; 
57: 213-25. 
(20) Dohrenwend BS. Social status and stressful life events. J Pers Soc Psychol 1973; 28: 225-
35. 
(21) Kristenson M, Eriksen HR, Sluiter JK, Starke D, Ursin H. Psychobiological mechanisms of 
socioeconomic differences in health. Social Science & Medicine 2004; 58: 1511-22. 
(22) Taylor SE, Seeman TE. Psychosocial resources and the SES-health relationship. Ann N Y 
Acad Sci 1999; 896: 210-25. 
(23) Rask K, O'Malley E, Druss B. Impact of socioeconomic, behavioral and clinical risk factors 
on mortality. J Public Health (Oxf) 2009; 31: 231-8. 
(24) Lantz PM, House JS, Lepkowski JM, Williams DR, Mero RP, Chen J. Socioeconomic factors, 
health behaviors, and mortality: results from a nationally representative prospective study of US 
adults. JAMA 1998; 279: 1703-8. 
(25) Seeman TE, Crimmins E, Huang MH, et al. Cumulative biological risk and socio-economic 
differences in mortality: MacArthur studies of successful aging. Soc Sci Med 2004; 58: 1985-97. 
(26) Schachter S, Silverstein B, Kozlowski LT, Herman CP, Liebling B. Effects of stress on 
cigarette smoking and urinary pH. J Exp Psychol Gen 1977; 106: 24-30. 
(27) Brunner E. Stress and the biology of inequality. BMJ 1997; 314: 1472-6. 
(28) Ng DM, Jeffery RW. Relationships between perceived stress and health behaviors in a 
sample of working adults. Health Psychol 2003; 22: 638-42. 
(29) Krueger PM, Chang VW. Being poor and coping with stress: health behaviors and the risk of 
death. Am J Public Health 2008; 98: 889-96. 
(30) Jung SH, Ostbye T, Park KO. A longitudinal study of the relationship between health 
behavior risk factors and dependence in activities of daily living. Journal of preventive medicine 
and public health = Yebang Uihakhoe chi 2006; 39: 221-8. 
(31) Smith GD, Hart C. Life-course socioeconomic and behavioral influences on cardiovascular 
disease mortality: the collaborative study. Am J Public Health 2002; 92: 1295-8. 
(32) Davis MA, Neuhaus JM, Moritz DJ, Lein D, Barclay JD, Murphy SP. Health behaviors and 
survival among middle-aged and older men and women in the NHANES I Epidemiologic Follow-





(33) Steptoe A, Wardle J, Pollard TM, Canaan L, Davies GJ. Stress, social support and health-
related behavior: a study of smoking, alcohol consumption and physical exercise. J Psychosom 
Res 1996; 41: 171-80. 
(34) Szanton SL, Gill JM, Allen JK. Allostatic load: a mechanism of socioeconomic health 
disparities? Biol Res Nurs 2005; 7: 7-15. 
(35) Carlson ED, Chamberlain RM. Allostatic load and health disparities: a theoretical orientation. 
Res Nurs Health 2005; 28: 306-15. 
(36) McEwen BS, Stellar E. Stress and the individual. Mechanisms leading to disease. Arch 
Intern Med 1993; 153: 2093-101. 
(37) Harald K, Koskinen S, Jousilahti P, Torppa J, Vartiainen E, Salomaa V. Changes in 
traditional risk factors no longer explain time trends in cardiovascular mortality and its 
socioeconomic differences. J Epidemiol Community Health 2008; 62: 251-7. 
(38) Aiello AE, Haan M, Blythe L, Moore K, Gonzalez JM, Jagust W. The influence of latent viral 
infection on rate of cognitive decline over 4 years. J Am Geriatr Soc 2006; 54: 1046-54. 
(39) Aiello AE, Haan MN, Pierce CM, Simanek AM, Liang J. Persistent infection, inflammation, 
and functional impairment in older latinos. J Gerontol A Biol Sci Med Sci 2008; 63: 610-8. 
(40) Simanek AM, Dowd JB, Aiello AE. Persistent pathogens linking socioeconomic position and 
cardiovascular disease in the US. Int J Epidemiol 2009; 38: 775-87. 
(41) Nabipour I, Vahdat K, Jafari S, Pazoki R, Sanjdideh Z. The association of metabolic 
syndrome and Chlamydia pneumoniae, Helicobacter pylori, cytomegalovirus, and herpes simplex 
virus type 1: The Persian Gulf Healthy Heart Study. Cardiovascular Diabetology 2006; 5: 25. 
(42) Sorlie PD, Adam E, Melnick SL, et al. Cytomegalovirus/herpesvirus and carotid 
atherosclerosis: the ARIC Study. J Med Virol 1994; 42: 33-7. 
(43) Gillum RF. Infection with Helicobacter pylori, coronary heart disease, cardiovascular risk 
factors, and systemic inflammation: The Third National Health and Nutrition Examination Survey. 
Journal of the National Medical Association 2004; 96: 1470-6. 
(44) Strandberg TE, Pitkala KH, Linnavuori KH, Tilvis RS. Impact of viral and bacterial burden on 
cognitive impairment in elderly persons with cardiovascular diseases. Stroke 2003; 34: 2126-31. 
(45) Melnick JL, Hu C, Burek J, Adam E, DeBakey ME. Cytomegalovirus DNA in arterial walls of 
patients with atherosclerosis. J Med Virol 1994; 42: 170-4. 
(46) Ibrahim AI, Obeid MT, Jouma MJ, et al. Detection of herpes simplex virus, cytomegalovirus 
and Epstein-Barr virus DNA in atherosclerotic plaques and in unaffected bypass grafts. J Clin 
Virol 2005; 32: 29-32. 
(47) Grahame-Clarke C. Human cytomegalovirus, endothelial function and atherosclerosis. 





(48) Shen YH, Utama B, Wang J, et al. Human Cytomegalovirus Causes Endothelial Injury 
Through the Ataxia Telangiectasia Mutant and p53 DNA Damage Signaling Pathways. Circ Res 
2004; 94: 1310-7. 
(49) Prasad A, Zhu J, Halcox JP, Waclawiw MA, Epstein SE, Quyyumi AA. Predisposition to 
atherosclerosis by infections: role of endothelial dysfunction. Circulation 2002; 106: 184-90. 
(50) Almeida GD, Porada CD, St Jeor S, Ascensao JL. Human cytomegalovirus alters interleukin-
6 production by endothelial cells. Blood 1994; 83: 370-6. 
(51) Soderberg-Naucler C. Does cytomegalovirus play a causative role in the development of 
various inflammatory diseases and cancer? J Intern Med 2006; 259: 219-46. 
(52) Roivainen M, Viik-Kajander M, Palosuo T, et al. Infections, inflammation, and the risk of 
coronary heart disease. Circulation 2000; 101: 252-7. 
(53) Nakou ES, Liberopoulos EN, Milionis HJ, Elisaf MS. The role of C-reactive protein in 
atherosclerotic cardiovascular disease: an overview. Curr Vasc Pharmacol 2008; 6: 258-70. 
(54) Kuo HK, Bean JF, Yen CJ, Leveille SG. Linking C-reactive protein to late-life disability in the 
National Health and Nutrition Examination Survey (NHANES) 1999-2002. J Gerontol A Biol Sci 
Med Sci 2006; 61: 380-7. 
(55) Kuo HK, Yen CJ, Chang CH, Kuo CK, Chen JH, Sorond F. Relation of C-reactive protein to 
stroke, cognitive disorders, and depression in the general population: systematic review and 
meta-analysis. Lancet Neurol 2005; 4: 371-80. 
(56) Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, 
and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-34. 
(57) Wang GC, Kao WH, Murakami P, et al. Cytomegalovirus infection and the risk of mortality 
and frailty in older women: a prospective observational cohort study. Am J Epidemiol 2010; 171: 
1144-52. 
(58) Roberts ET, Haan MN, Dowd JB, Aiello AE. Cytomegalovirus antibody levels, inflammation, 
and mortality among elderly Latinos over 9 years of follow-up. Am J Epidemiol 2010; 172: 363-71. 
(59) Strandberg TE, Pitkala KH, Tilvis RS. Cytomegalovirus antibody level and mortality among 
community-dwelling older adults with stable cardiovascular disease. JAMA 2009; 301: 380-2. 
(60) Zhu J, Nieto FJ, Horne BD, Anderson JL, Muhlestein JB, Epstein SE. Prospective study of 
pathogen burden and risk of myocardial infarction or death. Circulation 2001; 103: 45-51. 
(61) Rupprecht HJ, Blankenberg S, Bickel C, et al. Impact of viral and bacterial infectious burden 
on long-term prognosis in patients with coronary artery disease. Circulation 2001; 104: 25-31. 
(62) Espinola-Klein C, Rupprecht HJ, Blankenberg S, et al. Impact of Infectious Burden on Extent 
and Long-Term Prognosis of Atherosclerosis. Circulation 2002; 105: 15-21. 
(63) Britten RH. Risk of Mortality among Persons with Chronic Disease. Milbank Mem Fund Q 





(64) Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United 
States, 1970-2002. JAMA 2005; 294: 1255-9. 
(65) Baum A, Posluszny DM. Health psychology: mapping biobehavioral contributions to health 
and illness. Annu Rev Psychol 1999; 50: 137-63. 
(66) Lantz PM, Lynch JW, House JS, et al. Socioeconomic disparities in health change in a 
longitudinal study of US adults: the role of health-risk behaviors. Soc Sci Med 2001; 53: 29-40. 
(67) Staras SA, Dollard SC, Radford KW, Flanders WD, Pass RF, Cannon MJ. Seroprevalence of 
cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis 2006; 43: 1143-51. 
(68) Britt W. Manifestations of human cytomegalovirus infection: proposed mechanisms of acute 
and chronic disease. In: Anonymous Human Cytomegalovirus.; 2008. p. 417-418-470. 
(69) Mocarski Jr. ES, Hahn G, Lofgren White K, et al. Myeloid Cell Recruitment and Function in 
Pathogenesis and Latency. In: Reddehase MJ, editor. Cytomegaloviruses: Molecular Biology and 
Immunology. Norfolk, UK: Caister Academic Press; 2006. p. 465-466-482. 
(70) Nieto FJ, Adam E, Sorlie P, et al. Cohort study of cytomegalovirus infection as a risk factor 
for carotid intimal-medial thickening, a measure of subclinical atherosclerosis. Circulation 1996; 
94: 922-7. 
(71) Smieja M, Gnarpe J, Lonn E, et al. Multiple infections and subsequent cardiovascular events 
in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2003; 107: 251-7. 
(72) Samanta M, Harkins L, Klemm K, Britt WJ, Cobbs CS. High prevalence of human 
cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. J Urol 2003; 170: 
998-1002. 
(73) Harkins L, Volk AL, Samanta M, et al. Specific localisation of human cytomegalovirus nucleic 
acids and proteins in human colorectal cancer. Lancet 2002; 360: 1557-63. 
(74) Lin WR, Wozniak MA, Wilcock GK, Itzhaki RF. Cytomegalovirus is present in a very high 
proportion of brains from vascular dementia patients. Neurobiol Dis 2002; 9: 82-7. 
(75) Schmaltz HN, Fried LP, Xue QL, Walston J, Leng SX, Semba RD. Chronic cytomegalovirus 
infection and inflammation are associated with prevalent frailty in community-dwelling older 
women. J Am Geriatr Soc 2005; 53: 747-54. 
(76) Guetta E, Guetta V, Shibutani T, Epstein SE. Monocytes harboring cytomegalovirus: 
interactions with endothelial cells, smooth muscle cells, and oxidized low-density lipoprotein. 
Possible mechanisms for activating virus delivered by monocytes to sites of vascular injury. Circ 
Res 1997; 81: 8-16. 
(77) Melnick JL, Petrie BL, Dreesman GR, Burek J, McCollum CH, DeBakey ME. 
Cytomegalovirus antigen within human arterial smooth muscle cells. Lancet 1983; 2: 644-7. 
(78) Hendrix MG, Salimans MM, van Boven CP, Bruggeman CA. High prevalence of latently 
present cytomegalovirus in arterial walls of patients suffering from grade III atherosclerosis. Am J 





(79) Epstein SE, Zhu J, Najafi AH, Burnett MS. Insights into the role of infection in atherogenesis 
and in plaque rupture. Circulation 2009; 119: 3133-41. 
(80) Stassen FR, Vega-Cordova X, Vliegen I, Bruggeman CA. Immune activation following 
cytomegalovirus infection: more important than direct viral effects in cardiovascular disease? J 
Clin Virol 2006; 35: 349-53. 
(81) Reinhardt B, Mertens T, Mayr-Beyrle U, et al. HCMV infection of human vascular smooth 
muscle cells leads to enhanced expression of functionally intact PDGF beta-receptor. Cardiovasc 
Res 2005; 67: 151-60. 
(82) van Dam-Mieras MC, Muller AD, van Hinsbergh VW, Mullers WJ, Bomans PH, Bruggeman 
CA. The procoagulant response of cytomegalovirus infected endothelial cells. Thromb Haemost 
1992; 68: 364-70. 
(83) Albert LJ, Inman RD. Molecular mimicry and autoimmunity. N Engl J Med 1999; 341: 2068-
74. 
(84) Epstein SE, Zhu J, Burnett MS, Zhou YF, Vercellotti G, Hajjar D. Infection and 
atherosclerosis: potential roles of pathogen burden and molecular mimicry. Arterioscler Thromb 
Vasc Biol 2000; 20: 1417-20. 
(85) Bason C, Corrocher R, Lunardi C, et al. Interaction of antibodies against cytomegalovirus 
with heat-shock protein 60 in pathogenesis of atherosclerosis. Lancet 2003; 362: 1971-7. 
(86) Lunardi C, Dolcino M, Peterlana D, et al. Endothelial cells' activation and apoptosis induced 
by a subset of antibodies against human cytomegalovirus: relevance to the pathogenesis of 
atherosclerosis. PLoS One 2007; 2: e473. 
(87) Smith PD, Saini SS, Raffeld M, Manischewitz JF, Wahl SM. Cytomegalovirus induction of 
tumor necrosis factor-alpha by human monocytes and mucosal macrophages. J Clin Invest 1992; 
90: 1642-8. 
(88) Hansen SG, Powers CJ, Richards R, et al. Evasion of CD8+ T cells is critical for 
superinfection by cytomegalovirus. Science 2010; 328: 102-6. 
(89) Wikby A, Nilsson BO, Forsey R, et al. The immune risk phenotype is associated with IL-6 in 
the terminal decline stage: findings from the Swedish NONA immune longitudinal study of very 
late life functioning. Mech Ageing Dev 2006; 127: 695-704. 
(90) Krabbe KS, Pedersen M, Bruunsgaard H. Inflammatory mediators in the elderly. Exp 
Gerontol 2004; 39: 687-99. 
(91) Blankenberg S, Rupprecht HJ, Bickel C, et al. Cytomegalovirus infection with interleukin-6 
response predicts cardiac mortality in patients with coronary artery disease. Circulation 2001; 
103: 2915-21. 
(92) Muhlestein JB, Horne BD, Carlquist JF, et al. Cytomegalovirus seropositivity and C-reactive 
protein have independent and combined predictive value for mortality in patients with 





(93) Konturek PC, Konturek SJ, Brzozowski T. Helicobacter pylori infection in gastric 
cancerogenesis. J Physiol Pharmacol 2009; 60: 3-21. 
(94) Epstein SE. The multiple mechanisms by which infection may contribute to atherosclerosis 
development and course. Circ Res 2002; 90: 2-4. 
(95) Espinola-Klein C, Rupprecht HJ, Blankenberg S, et al. Impact of infectious burden on 
progression of carotid atherosclerosis. Stroke 2002; 33: 2581-6. 
(96) Etingin OR, Silverstein RL, Friedman HM, Hajjar DP. Viral activation of the coagulation 
cascade: molecular interactions at the surface of infected endothelial cells. Cell 1990; 61: 657-62. 
(97) Gredmark S, Jonasson L, Van Gosliga D, Ernerudh J, Soderberg-Naucler C. Active 
cytomegalovirus replication in patients with coronary disease. Scand Cardiovasc J 2007; 41: 230-
4. 
(98) Nieto FJ. Infections and atherosclerosis: New clues from an old hypothesis? American 
Journal of Epidemiology 1998; 148: 937-48. 
(99) Sorlie PD, Nieto FJ, Adam E, Folsom AR, Shahar E, Massing M. A Prospective Study of 
Cytomegalovirus, Herpes Simplex Virus 1, and Coronary Heart Disease: The Atherosclerosis 
Risk in Communities (ARIC) Study. Arch Intern Med 2000; 160: 2027-32. 
(100) Schlitt A, Blankenberg S, Weise K, et al. Herpesvirus DNA (Epstein-Barr virus, herpes 
simplex virus, cytomegalovirus) in circulating monocytes of patients with coronary artery disease. 
Acta Cardiol 2005; 60: 605-10. 
(101) Kim DK, Kim HJ, Han SH, et al. Chlamydia pneumoniae accompanied by inflammation is 
associated with the progression of atherosclerosis in CAPD patients: a prospective study for 3 
years. Nephrol Dial Transplant 2007;. 
(102) Mendall MA, Goggin PM, Molineaux N, et al. Relation of Helicobacter pylori infection and 
coronary heart disease. Br Heart J 1994; 71: 437-9. 
(103) Ford PJ, Yamazaki K, Seymour GJ. Cardiovascular and oral disease interactions: what is 
the evidence? Prim Dent Care 2007; 14: 59-66. 
(104) Paquette DW, Brodala N, Nichols TC. Cardiovascular disease, inflammation, and 
periodontal infection. Periodontol 2000 2007; 44: 113-26. 
(105) Madjid M, Naghavi M, Litovsky S, Casscells SW. Influenza and cardiovascular disease: a 
new opportunity for prevention and the need for further studies. Circulation 2003; 108: 2730-6. 
(106) Leinonen M, Saikku P. Evidence for infectious agents in cardiovascular disease and 
atherosclerosis. Lancet Infect Dis 2002; 2: 11-7. 
(107) Matsuura E, Kobayashi K, Matsunami Y, et al. Autoimmunity, Infectious Immunity, and 
Atherosclerosis. J Clin Immunol 2009;. 
(108) Manolakis A, Kapsoritakis AN, Potamianos SP. A review of the postulated mechanisms 






(109) Ferreira AC, Isomoto H, Moriyama M, Fujioka T, Machado JC, Yamaoka Y. Helicobacter 
and gastric malignancies. Helicobacter 2008; 13 Suppl 1: 28-34. 
(110) Kutok JL, Wang F. Spectrum of Epstein-Barr virus-associated diseases. Annu Rev Pathol 
2006; 1: 375-404. 
(111) Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary 
cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-9. 
(112) Sinclair J, Sissons P. Latency and reactivation of human cytomegalovirus. Journal of 
General Virology 2006; 87: 1763-79. 
(113) Glaser, R., Kiecolt-Glaser,JK. Stress-Associated Immune Modulation and Its Implications 
for Reactivation of Latent Herpesviruses. In: (Eds.) RG&JJ, editor. Human herpesvirus infections. 
New York: Dekker; 1994. p. 245-270. 
(114) Glaser R, Kiecolt-Glaser JK. Chronic stress modulates the virus-specific immune response 
to latent herpes simplex virus type 1. Ann Behav Med 1997; 19: 78-82. 
(115) Limaye AP, Kirby KA, Rubenfeld GD, et al. Cytomegalovirus reactivation in critically ill 
immunocompetent patients. JAMA 2008; 300: 413-22. 
(116) Graham DY, Osato MS. H. pylori in the pathogenesis of duodenal ulcer: interaction 
between duodenal acid load, bile, and H. pylori. Am J Gastroenterol 2000; 95: 87-91. 
(117) Lee A, Dixon MF, Danon SJ, et al. Local acid production and Helicobacter pylori: a unifying 
hypothesis of gastroduodenal disease. Eur J Gastroenterol Hepatol 1995; 7: 461-5. 
(118) Tice JA, Browner W, Tracy RP, Cummings SR. The relation of C-reactive protein levels to 
total and cardiovascular mortality in older U.S. women. Am J Med 2003; 114: 199-205. 
(119) Elkind MS, Ramakrishnan P, Moon YP, et al. Infectious burden and risk of stroke: the 
northern Manhattan study. Arch Neurol 2010; 67: 33-8. 
(120) Miggins M, Hasan A, Hohmann S, Southwick F, Casella G. The Potential Influence of 
Common Viral Infections Diagnosed during Hospitalization among Critically Ill Patients in the 
United States. PLoS One 2011; 6: e18890. 
(121) Wanishsawad C, Zhou YF, Epstein SE. Chlamydia pneumoniae-induced transactivation of 
the major immediate early promoter of cytomegalovirus: potential synergy of infectious agents in 
the pathogenesis of atherosclerosis. J Infect Dis 2000; 181: 787-90. 
(122) Tsamakidis K, Panotopoulou E, Dimitroulopoulos D, et al. Herpes simplex virus type 1 in 
peptic ulcer disease: an inverse association with Helicobacter pylori. World J Gastroenterol 2005; 
11: 6644-9. 
(123) Staras SA, Flanders WD, Dollard SC, Pass RF, McGowan JE,Jr, Cannon MJ. Influence of 
sexual activity on cytomegalovirus seroprevalence in the United States, 1988-1994. Sex Transm 
Dis 2008; 35: 472-9. 
(124) Stassen FR, Vainas T, Bruggeman CA. Infection and atherosclerosis. An alternative view 





(125) Hsich E, Zhou YF, Paigen B, Johnson TM, Burnett MS, Epstein SE. Cytomegalovirus 
infection increases development of atherosclerosis in Apolipoprotein-E knockout mice. 
Atherosclerosis 2001; 156: 23-8. 
(126) Berencsi K, Endresz V, Klurfeld D, Kari L, Kritchevsky D, Gonczol E. Early atherosclerotic 
plaques in the aorta following cytomegalovirus infection of mice. Cell Adhes Commun 1998; 5: 
39-47. 
(127) Hendrix MG, Salimans MM, van Boven CP, Bruggeman CA. High prevalence of latently 
present cytomegalovirus in arterial walls of patients suffering from grade III atherosclerosis. Am J 
Pathol 1990; 136: 23-8. 
(128) Olsson J, Wikby A, Johansson B, Lofgren S, Nilsson BO, Ferguson FG. Age-related 
change in peripheral blood T-lymphocyte subpopulations and cytomegalovirus infection in the 
very old: the Swedish longitudinal OCTO immune study. Mech Ageing Dev 2000; 121: 187-201. 
(129) Wikby A, Johansson B, Ferguson F, Olsson J. Age-related changes in immune parameters 
in a very old population of Swedish people: a longitudinal study. Exp Gerontol 1994; 29: 531-41. 
(130) Wikby A, Ferguson F, Forsey R, et al. An immune risk phenotype, cognitive impairment, 
and survival in very late life: impact of allostatic load in Swedish octogenarian and nonagenarian 
humans. J Gerontol A Biol Sci Med Sci 2005; 60: 556-65. 
(131) Hadrup SR, Strindhall J, Kollgaard T, et al. Longitudinal studies of clonally expanded CD8 T 
cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional 
cytomegalovirus-specific T cells in the very elderly. J Immunol 2006; 176: 2645-53. 
(132) Pawelec G, Derhovanessian E, Larbi A, Strindhall J, Wikby A. Cytomegalovirus and human 
immunosenescence. Rev Med Virol 2009; 19: 47-56. 
(133) Chidrawar S, Khan N, Wei W, et al. Cytomegalovirus-seropositivity has a profound 
influence on the magnitude of major lymphoid subsets within healthy individuals. Clin Exp 
Immunol 2009; 155: 423-32. 
(134) Looney RJ, Falsey A, Campbell D, et al. Role of cytomegalovirus in the T cell changes seen 
in elderly individuals. Clin Immunol 1999; 90: 213-9. 
(135) Zhu J, Quyyumi AA, Norman JE, Csako G, Epstein SE. Cytomegalovirus in the 
pathogenesis of atherosclerosis: the role of inflammation as reflected by elevated C-reactive 
protein levels. J Am Coll Cardiol 1999; 34: 1738-43. 
(136) Mendall MA, Strachan DP, Butland BK, et al. C-reactive protein: relation to total mortality, 
cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J 2000; 21: 1584-90. 
(137) Harris TB, Ferrucci L, Tracy RP, et al. Associations of elevated interleukin-6 and C-reactive 
protein levels with mortality in the elderly. Am J Med 1999; 106: 506-12. 
(138) Ridker PM, Hennekens CH, Stampfer MJ, Wang F. Prospective study of herpes simplex 






(139) Knosel T, Schewe C, Dietel M, Petersen I. Cytomegalovirus is not associated with 
progression and metastasis of colorectal cancer. Cancer Lett 2004; 211: 243-7. 
(140) National Center for Health Statistics. Office of Analysis and Epidemiology, TheThird 
National Health and Nutrition Examination Survey(NHANES III) Linked Mortality File, Mortality 
follow-up through 2006: Matching Methodology May 2009. 
(141) National Health and Nutrition Examination Survey III: 1988-1994.  Documation, Codebook, 
and Frequencies: Antibody to Cytomegalovirus IgG and IgM. 2005. 
(142) Gunter EW, Lewis BG, Koncikowski SM. Laboratory procedures used for the Third National 
Health and Nutrition Examination Survey (NHANES III), 1988-1994. Atlanta, Ga: U.S. Department 
of Health and Human Services, Public Health Service, Centers for Disease Control and 
Prevention, National Center for Environmental Health, 1996. . 
(143) Ridker PM. Cardiology Patient Page. C-reactive protein: a simple test to help predict risk of 
heart attack and stroke. Circulation 2003; 108: e81-5. 
(144) National Center for health Statistics. The National Health and Nutrition Examination Survey 
(NHANES III) Linked Mortality File Public-use Detailed Notes for Selected Variables. . 2010. 
(145) Dowd JB, Aiello AE, Alley DE. Socioeconomic disparities in the seroprevalence of 
cytomegalovirus infection in the US population: NHANES III. Epidemiol Infect 2009; 137: 58-65. 
(146) Arcavi L, Benowitz NL. Cigarette smoking and infection. Arch Intern Med 2004; 164: 2206-
16. 
(147) Bertoni AG, Saydah S, Brancati FL. Diabetes and the risk of infection-related mortality in 
the U.S. Diabetes Care 2001; 24: 1044-9. 
(148) Singh GK, Hiatt RA. Trends and disparities in socioeconomic and behavioural 
characteristics, life expectancy, and cause-specific mortality of native-born and foreign-born 
populations in the United States, 1979-2003. Int J Epidemiol 2006; 35: 903-19. 
(149) Galobardes B, Lynch J, Smith GD. Measuring socioeconomic position in health research. 
Br Med Bull 2007; 81-82: 21-37. 
(150) Shavers VL. Measurement of socioeconomic status in health disparities research. J Natl 
Med Assoc 2007; 99: 1013-23. 
(151) Prasad K. C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev 2006; 24: 33-50. 
(152) Lee TA, Bartle B, Weiss KB. Impact of NSAIDS on mortality and the effect of preexisting 
coronary artery disease in US veterans. Am J Med 2007; 120: 98.e9,98.16. 
(153) National Center for Health Statistics. National Health and Nutrition Examination Survey III: 
1988-1994.  Partial Household Adult Data File Documentation. 1998;. 
(154) National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, 
and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the 





Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 
2002; 106: 3143-421. 
(155) Research Triangle Institute. SUDAAN Example Manual, Release 10.0.1. 2010 
(156) Rothman, K.J. and Greenland, S. Modern Epidemiology. Boston: Lippincott Williams & 
Wilkins; 1998. 
(157) Costalonga EC, Melo NC, Rodrigues CE, Sette LH, Ianhez LE. The potential role of C-
reactive protein in distinguishing cytomegalovirus from tuberculosis and bacterial infections in 
renal transplant recipients. Clin Transplant 2009; 23: 710-5. 
(158) Chan D, Ng LL. Biomarkers in acute myocardial infarction. BMC Med 2010; 8: 34. 
(159) Bajpai A, Goyal A, Sperling L. Should we measure C-reactive protein on earth or just on 
JUPITER? Clin Cardiol 2010; 33: 190-8. 
(160) He LP, Tang XY, Ling WH, Chen WQ, Chen YM. Early C-reactive protein in the prediction 
of long-term outcomes after acute coronary syndromes: a meta-analysis of longitudinal studies. 
Heart 2010; 96: 339-46. 
(161) Kuper H, Nicholson A, Kivimaki M, et al. Evaluating the causal relevance of diverse risk 
markers: horizontal systematic review. BMJ 2009; 339: b4265. 
(162) Data Linkage Team. Comparative analysis of the NHANES III public-use and restricted-use 
linked mortality files: 2010 public-use data release. 2010;. 
(163) Sathiakumar N, Delzell E, Abdalla O. Using the National Death Index to obtain underlying 
cause of death codes. J Occup Environ Med 1998; 40: 808-13. 
(164) Rose G. Sick individuals and sick populations. Int J Epidemiol 2001; 30: 427,32; discussion 
433-4. 
(165) Colugnati FA, Staras SA, Dollard SC, Cannon MJ. Incidence of cytomegalovirus infection 
among the general population and pregnant women in the United States. BMC Infect Dis 2007; 7: 
71. 
(166) Siscovick DS, Schwartz SM, Corey L, et al. Chlamydia pneumoniae, herpes simplex virus 
type 1, and cytomegalovirus and incident myocardial infarction and coronary heart disease death 
in older adults: The cardiovascular health study. Circulation 2000; 102: 2335-40. 
(167) Strandberg TE, Pitkala KH, Linnavuori K, Tilvis RS. Cognitive impairment and infectious 
burden in the elderly. Arch Gerontol Geriatr Suppl 2004; (9): 419-23. 
(168) Degens H. The role of systemic inflammation in age-related muscle weakness and wasting. 
Scand J Med Sci Sports 2010; 20: 28-38. 
(169) Brinkley TE, Leng X, Miller ME, et al. Chronic Inflammation Is Associated With Low 






(170) Carriere I, Dupuy AM, Lacroux A, Cristol JP, Delcourt C, Pathologies Oculaires Liees a 
l'Age Study Group. Biomarkers of inflammation and malnutrition associated with early death in 
healthy elderly people. J Am Geriatr Soc 2008; 56: 840-6. 
(171) Allavena P, Garlanda C, Borrello MG, Sica A, Mantovani A. Pathways connecting 
inflammation and cancer. Curr Opin Genet Dev 2008; 18: 3-10. 
(172) Jackson L, Britton J, Lewis SA, et al. A population-based epidemiologic study of 
Helicobacter pylori infection and its association with systemic inflammation. Helicobacter 2009; 
14: 108-13. 
(173) Itzhaki RF, Dobson CB, Shipley SJ, Wozniak MA. The role of viruses and of APOE in 
dementia. Ann N Y Acad Sci 2004; 1019: 15-8. 
(174) Sun Y, Pei W, Wu Y, Jing Z, Zhang J, Wang G. Herpes simplex virus type 2 infection is a 
risk factor for hypertension. Hypertens Res 2004; 27: 541-4. 
(175) Schillinger JA, Xu F, Sternberg MR, et al. National seroprevalence and trends in herpes 
simplex virus type 1 in the United States, 1976-1994. Sex Transm Dis 2004; 31: 753-60. 
(176) Lee FK, Pereira L, Griffin C, Reid E, Nahmias A. A novel glycoprotein for detection of 
herpes simplex virus type 1-specific antibodies. J Virol Methods 1986; 14: 111-8. 
(177) U.S. Department of Health and Human Services (DHHS). National Center for Health 
Statistics. Third National Health and Nutrition Examination Survey, 1988-1994, NHANES III 
Second Laboratory Data File (CD-ROM, Series 11, No. 3A). 1999;. 
(178) Nazmi A, Diez-Roux AV, Jenny NS, Tsai MY, Szklo M, Aiello AE. The influence of 
persistent pathogens on circulating levels of inflammatory markers: a cross-sectional analysis 
from the Multi-Ethnic Study of Atherosclerosis. BMC Public Health 2010; 10: 706. 
(179) Fernandez-Real JM, Ferri MJ, Vendrell J, Ricart W. Burden of infection and fat mass in 
healthy middle-aged men. Obesity (Silver Spring) 2007; 15: 245-52. 
(180) Fernandez-Real J, Lopez-Bermejo A, Vendrell J, Ferri M, Recasens M, Ricart W. Burden of 
Infection and Insulin Resistance in Healthy Middle-Aged Men. Diabetes Care 2006; 29: 1058-64. 
(181) Georges JL, Rupprecht HJ, Blankenberg S, et al. Impact of pathogen burden in patients 
with coronary artery disease in relation to systemic inflammation and variation in genes encoding 
cytokines. Am J Cardiol 2003; 92: 515-21. 
(182) Liu R, Moroi M, Yamamoto M, et al. Presence and severity of Chlamydia pneumoniae and 
cytomegalovirus infection in coronary plaques are associated with acute coronary syndromes. 
International Heart Journal 2006; 47: 511-9. 
(183) Saikku P, Leinonen M, Tenkanen L, et al. Chronic Chlamydia pneumoniae infection as a 






(184) Strachan DP, Carrington D, Mendall MA, et al. Relation of Chlamydia pneumoniae serology 
to mortality and incidence of ischaemic heart disease over 13 years in the caerphilly prospective 
heart disease study. BMJ 1999; 318: 1035-9. 
